Artificial antibody polypeptides

ABSTRACT

A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, k cat , and an uncatalyzed rate constant, k uncat , such that the ratio of k cat /k uncat  is greater than 10.

[0001] This application is a continuation under 37 C.F.R. 1.53(b) ofU.S. Ser. No. 09/096,749, filed Jun. 12, 1998, which claims priorityunder 35 U.S.C. 119(e) to provisional application U.S. Ser. No.60/049,410, filed Jun. 12, 1997, which applications are incorporatedherein by reference.

FIELD OF THE INVENTION

[0002] The present invention relates generally to the field of theproduction and selection of binding and catalytic polypeptides by themethods of molecular biology, using both combinatorial chemistry andrecombinant DNA. The invention specifically relates to the generation ofboth nucleic acid and polypeptide libraries derived therefrom encodingthe molecular scaffolding of Fibronectin Type III (Fn3) modified in oneor more of its loop regions. The invention also relates to the“artificial mini-antibodies” or “monobodies,” i.e., the polypeptidescomprising an Fn3 scaffold onto which loop regions capable of binding toa variety of different molecular structures (such as antibody bindingsites) have been grafted.

BACKGROUND OF THE INVENTION

[0003] Antibody structure

[0004] A standard antibody (Ab) is a tetrameric structure consisting oftwo identical immunoglobulin (Ig) heavy chains and two identical lightchains. The heavy and light chains of an Ab consist of differentdomains. Each light chain has one variable domain (VL) and one constantdomain (CL), while each heavy chain has one variable domain (VH) andthree or four constant domains (CH) (Alzari et al., 1988). Each domain,consisting of ˜110 amino acid residues, is folded into a characteristicβ-sandwich structure formed from two β-sheets packed against each other,the immunoglobulin fold. The VH and VL domains each have threecomplementarity determining regions (CDR1-3) that are loops, or turns,connecting β-strands at one end of the domains (FIGS. 1: A, C). Thevariable regions of both the light and heavy chains generally contributeto antigen specificity, although the contribution of the individualchains to specificity is not always equal. Antibody molecules haveevolved to bind to a large number of molecules by using six randomizedloops (CDRs). However, the size of the antibodies and the complexity ofsix loops represents a major design hurdle if the end result is to be arelatively small peptide ligand.

[0005] Antibody Substructures

[0006] Functional substructures of Abs can be prepared by proteolysisand by recombinant methods. They include the Fab fragment, whichcomprises the VH-CH1 domains of the heavy chain and the VL-CL1 domainsof the light chain joined by a single interchain disulfide bond, and theFv fragment, which comprises only the VH and VL domains. In some cases,a single VH domain retains significant affinity (Ward et al., 1989). Ithas also been shown that a certain monomeric κ light chain willspecifically bind to its cognate antigen. (L. Masat et al., 1994).Separated light or heavy chains have sometimes been found to retain someantigen-binding activity (Ward et al., 1989). These antibody fragmentsare not suitable for structural analysis using NMR spectroscopy due totheir size, low solubility or low conformational stability.

[0007] Another functional substructure is a single chain Fv (scFv),comprised of the variable regions of the immunoglobulin heavy and lightchain, covalently connected by a peptide linker (S-z Hu et al., 1996).These small (M, 25,000) proteins generally retain specificity andaffinity for antigen in a single polypeptide and can provide aconvenient building block for larger, antigen-specific molecules.Several groups have reported biodistribution studies in xenograftedathymic mice using scFv reactive against a variety of tumor antigens, inwhich specific tumor localization has been observed. However, the shortpersistence of scFvs in the circulation limits the exposure of tumorcells to the scFvs, placing limits on the level of uptake. As a result,tumor uptake by scFvs in animal studies has generally been only 1-5%ID/g as opposed to intact antibodies that can localize in tumors ad30-40% ID/g and have reached levels as high as 60-70% ID/g.

[0008] A small protein scaffold called a “minibody” was designed using apart of the Ig VH domain as the template (Pessi et al., 1993).Minibodies with high affinity (dissociation constant (K_(d))˜10⁻⁷ M) tointerleukin-6 were identified by randomizing loops corresponding to CDR1and CDR2 of VH and then selecting mutants using the phage display method(Martin et al., 1994). These experiments demonstrated that the essenceof the Ab function could be transferred to a smaller system. However,the minibody had inherited the limited solubility of the VH domain(Bianchi et al., 1994).

[0009] It has been reported that camels (Camelus dromedarius) often lackvariable light chain domains when IgG-like material from their serum isanalyzed, suggesting that sufficient antibody specificity and affinitycan be derived form VH domains (three CDR loops) alone. Davies andRiechmann recently demonstrated that “camelized” VH domains with highaffinity (K_(d)˜10⁻⁷ M) and high specificity can be generated byrandomizing only the CDR3. To improve the solubility and suppressnonspecific binding, three mutations were introduced to the frameworkregion (Davies & Riechmann, 1995). It has not been definitively shown,however, that camelization can be used, in general, to improve thesolubility and stability of VHs.

[0010] An alternative to the “minibody” is the “diabody.” Diabodies aresmall bivalent and bispecific antibody fragments, i.e., they have twoantigen-binding sites. The fragments comprise a heavy-chain variabledomain (V_(H)) connected to a light-chain variable domain (V_(L)) on thesame polypeptide chain (V_(H)-V_(L)). Diabodies are similar in size toan Fab fragment. By using a linker that is too short to allow pairingbetween the two domains on the same chain, the domains are forced topair with the complementary domains of another chain and create twoantigen-binding sites. These dimeric antibody fragments, or “diabodies,”are bivalent and bispecific. P. Holliger et al., PNAS 90:6444-6448(1993).

[0011] Since the development of the monoclonal antibody technology, alarge number of 3D structures of Ab fragments in the complexed and/orfree states have been solved by X-ray crystallography (Webster et al.,1994; Wilson & Stanfield, 1994). Analysis of Ab structures has revealedthat five out of the six CDRs have limited numbers of peptide backboneconformations, thereby permitting one to predict the backboneconformation of CDRs using the so-called canonical structures (Lesk &Tramontano, 1992; Rees et al., 1994). The analysis also has revealedthat the CDR3 of the VH domain (VH-CDR3) usually has the largest contactsurface and that its conformation is too diverse for canonicalstructures to be defined; VH-CDR3 is also known to have a largevariation in length (Wu et al., 1993). Therefore, the structures ofcrucial regions of the Ab-antigen interface still need to beexperimentally determined.

[0012] Comparison of crystal structures between the free and complexedstates has revealed several types of conformational rearrangements. Theyinclude side-chain rearrangements, segmental movements, largerearrangements of VH-CDR3 and changes in the relative position of the VHand VL domains (Wilson & Stanfield, 1993). In the free state, CDRs, inparticular those which undergo large conformational changes uponbinding, are expected to be flexible. Since X-ray crystallography is notsuited for characterizing flexible parts of molecules, structuralstudies in the solution state have not been possible to provide dynamicpictures of the conformation of antigen-binding sites.

[0013] Mimicking the Antibody-binding Site

[0014] CDR peptides and organic CDR mimetics have been made (Dougall etal., 1994). CDR peptides are short, typically cyclic, peptides whichcorrespond to the amino acid sequences of CDR loops of antibodies. CDRloops are responsible for antibody-antigen interactions. Organic CDRmimetics are peptides corresponding to CDR loops which are attached to ascaffold, e.g., a small organic compound.

[0015] CDR peptides and organic CDR mimetics have been shown to retainsome binding affinity (Smyth & von Itzstein, 1994). However, asexpected, they are too small and too flexible to maintain full affinityand specificity. Mouse CDRs have been grafted onto the human Igframework without the loss of affinity (Jones et al., 1986; Riechmann etal., 1988), though this “humanization” does not solve theabove-mentioned problems specific to solution studies.

[0016] Mimicking Natural Selection Processes of Abs

[0017] In the immune system, specific Abs are selected and amplifiedfrom a large library (affinity maturation). The processes can bereproduced in vitro using combinatorial library technologies. Thesuccessful display of Ab fragments on the surface of bacteriophage hasmade it possible to generate and screen a vast number of CDR mutations(McCafferty et al., 1990; Barbas et al., 1991; Winter et al., 1994). Anincreasing number of Fabs and Fvs (and their derivatives) is produced bythis technique, providing a rich source for structural studies. Thecombinatorial technique can be combined with Ab mimics.

[0018] A number of protein domains that could potentially serve asprotein scaffolds have been expressed as fusions with phage capsidproteins. Review in Clackson & Wells, Trends Biotechnol. 12:173-184(1994). Indeed, several of these protein domains have already been usedas scaffolds for displaying random peptide sequences, including bovinepancreatic trypsin inhibitor (Roberts et al., PNAS 89:2429-2433 (1992)),human growth hormone (Lowman et al., Biochemistry 30:10832-10838(1991)), Venturini et al., Protein Peptide Letters 1:70-75 (1994)), andthe IgG binding domain of Streptococcus (O'Neil et al., Techniques inProtein Chemistry V (Crabb, L,. ed.) pp. 517-524, Academic Press, SanDiego (1994)). These scaffolds have displayed a single randomized loopor region.

[0019] Researchers have used the small 74 amino acid α-amylase inhibitorTendamistat as a presentation scaffold on the filamentous phage M13(McConnell and Hoess, 1995). Tendamistat is a i-sheet protein fromStreptomyces tendae. It has a number of features that make it anattractive scaffold for peptides, including its small size, stability,and the availability of high resolution NMR and X-ray structural data.Tendamistat's overall topology is similar to that of an immunoglobulindomain, with two β-sheets connected by a series of loops. In contrast toimmunoglobulin domains, the β-sheets of Tendamistat are held togetherwith two rather than one disulfide bond, accounting for the considerablestability of the protein. By analogy with the CDR loops found inimmunoglobulins, the loops the Tendamistat may serve a similar functionand can be easily randomized by in vitro mutagenesis.

[0020] Tendamistat, however, is derived from Streptomyces tendae. Thus,while Tendamistat may be antigenic in humans, its small size may reduceor inhibit its antigenicity. Also, Tendamistat's stability is uncertain.Further, the stability that is reported for Tendamistat is attributed tothe presence of two disulfide bonds. Disulfide bonds, however, are asignificant disadvantage to such molecules in that they can be brokenunder reducing conditions and must be properly formed in order to have auseful protein structure. Further, the size of the loops in Tendamistatare relatively small, thus limiting the size of the inserts that can beaccommodated in the scaffold. Moreover, it is well known that formingcorrect disulfide bonds in newly synthesized peptides is notstraightforward. When a protein is expressed in the cytoplasmic space ofE. coli, the most common host bacterium for protein overexpression,disulfide bonds are usually not formed, potentially making it difficultto prepare large quantities of engineered molecules.

[0021] Thus, there is an on-going need for small, single-chainartificial antibodies for a variety of therapeutic, diagnostic andcatalytic applications.

SUMMARY OF THE INVENTION

[0022] The invention provides a fibronectin type III (Fn3) polypeptidemonobody comprising a plurality of Fn3 β-strand domain sequences thatare linked to a plurality of loop region sequences. One or more of themonobody loop region sequences of the Fn3 polypeptide vary by deletion,insertion or replacement of at least two amino acids from thecorresponding loop region sequences in wild-type Fn3. The β-stranddomains of the monobody have at least about 50% total amino acidsequence homology to the corresponding amino acid sequence of wild-typeFn3's β-strand domain sequences. Preferably, one or more of the loopregions of the monobody comprise amino acid residues:

[0023] i) from 15 to 16 inclusive in an AB loop;

[0024] ii) from 22 to 30 inclusive in a BC loop;

[0025] iii) from 39 to 45 inclusive in a CD loop;

[0026] iv) from 51 to 55 inclusive in a DE loop;

[0027] v) from 60 to 66 inclusive in an EF loop; and

[0028] vi) from 76 to 87 inclusive in an FG loop.

[0029] The invention also provides a nucleic acid molecule encoding aFn3 polypeptide monobody of the invention, as well as an expressionvector comprising said nucleic acid molecule and a host cell comprisingsaid vector.

[0030] The invention further provides a method of preparing a Fn3polypeptide monobody. The method comprises providing a DNA sequenceencoding a plurality of Fn3 β-strand domain sequences that are linked toa plurality of loop region sequences, wherein at least one loop regionof said sequence contains a unique restriction enzyme site. The DNAsequence is cleaved at the unique restriction site. Then a preselectedDNA segment is inserted into the restriction site. The preselected DNAsegment encodes a peptide capable of binding to a specific bindingpartner (SBP) or a transition state analog compound (TSAC). Theinsertion of the preselected DNA segment into the DNA sequence yields aDNA molecule which encodes a polypeptide monobody having an insertion.The DNA molecule is then expressed so as to yield the polypeptidemonobody.

[0031] Also provided is a method of preparing a Fn3 polypeptidemonobody, which method comprises providing a replicatable DNA sequenceencoding a plurality of Fn3 β-strand domain sequences that are linked toa plurality of loop region sequences, wherein the nucleotide sequence ofat least one loop region is known. Polymerase chain reaction (PCR)primers are provided or prepared which are sufficiently complementary tothe known loop sequence so as to be hybridizable under PCR conditions,wherein at least one of the primers contains a modified nucleic acidsequence to be inserted into the DNA sequence. PCR is performed usingthe replicatable DNA sequence and the primers. The reaction product ofthe PCR is then expressed so as to yield a polypeptide monobody.

[0032] The invention further provides a method of preparing a Fn3polypeptide monobody. The method comprises providing a replicatable DNAsequence encoding a plurality of Fn3 β-strand domain sequences that arelinked to a plurality of loop region sequences, wherein the nucleotidesequence of at least one loop region is known. Site-directed mutagenesisof at least one loop region is performed so as to create an insertionmutation. The resultant DNA comprising the insertion mutation is thenexpressed.

[0033] Further provided is a variegated nucleic acid library encodingFn3 polypeptide monobodies comprising a plurality of nucleic acidspecies encoding a plurality of Fn3 β-strand domain sequences that arelinked to a plurality of loop region sequences, wherein one or more ofthe monobody loop region sequences vary by deletion, insertion orreplacement of at least two amino acids from corresponding loop regionsequences in wild-type Fn3, and wherein the β-strand domains of themonobody have at least a 50% total amino acid sequence homology to thecorresponding amino acid sequence of β-strand domain sequences of thewild-type Fn3. The invention also provides a peptide display libraryderived from the variegated nucleic acid library of the invention.Preferably, the peptide of the peptide display library is displayed onthe surface of a bacteriophage, e.g., a M13 bacteriophage or a fdbacteriophage, or virus.

[0034] The invention also provides a method of identifying the aminoacid sequence of a polypeptide molecule capable of binding to a specificbinding partner (SBP) so as to form a polypeptide:SSP complex, whereinthe dissociation constant of the said polypeptide:SBP complex is lessthan 10⁻⁶ moles/liter. The method comprises the steps of:

[0035] a) providing a peptide display library of the invention;

[0036] b) contacting the peptide display library of (a) with animmobilized or separable SBP;

[0037] c) separating the peptide:SBP complexes from the free peptides;

[0038] d) causing the replication of the separated peptides of (c) so asto result in a new peptide display library distinguished from that in(a) by having a lowered diversity and by being enriched in displayedpeptides capable of binding the SBP;

[0039] e) optionally repeating steps (b), (c), and (d) with the newlibrary of (d); and

[0040] f) determining the nucleic acid sequence of the region encodingthe displayed peptide of a species from (d) and hence deducing thepeptide sequence capable of binding to the SBP.

[0041] The present invention also provides a method of preparing avariegated nucleic acid library encoding Fn3 polypeptide monobodieshaving a plurality of nucleic acid species each comprising a pluralityof loop regions, wherein the species encode a plurality of Fn3 β-stranddomain sequences that are linked to a plurality of loop regionsequences, wherein one or more of the loop region sequences vary bydeletion, insertion or replacement of at least two amino acids fromcorresponding loop region sequences in wild-type Fn3, and wherein theβ-strand domain sequences of the monobody have at least a 50% totalamino acid sequence homology to the corresponding amino acid sequencesof β-strand domain sequences of the wild-type Fn3, comprising the stepsof

[0042] a) preparing an Fn3 polypeptide monobody having a predeterminedsequence;

[0043] b) contacting the polypeptide with a specific binding partner(SBP) so as to form a polypeptide:SSP complex wherein the dissociationconstant of the said polypeptide:SBP complex is less than 10⁻⁶moles/liter;

[0044] c) determining the binding structure of the polypeptide:SBPcomplex by nuclear magnetic resonance spectroscopy or X-raycrystallography; and

[0045] d) preparing the variegated nucleic acid library, wherein thevariegation is performed at positions in the nucleic acid sequencewhich, from the information provided in (c), result in one or morepolypeptides with improved binding to the SBP.

[0046] Also provided is a method of identifying the amino acid sequenceof a polypeptide molecule capable of catalyzing a chemical reaction witha catalyzed rate constant, k_(cat), and an uncatalyzed rate constant,k_(uncat), such that the ratio of k_(cat)/k_(uncat) is greater than 10.The method comprises the steps of:

[0047] a) providing a peptide display library of the invention;

[0048] b) contacting the peptide display library of (a) with animmobilized or separable transition state analog compound (TSAC)representing the approximate molecular transition state of the chemicalreaction;

[0049] c) separating the peptide:TSAC complexes from the free peptides;

[0050] d) causing the replication of the separated peptides of (c) so asto result in a new peptide display library distinguished from that in(a) by having a lowered diversity and by being enriched in displayedpeptides capable of binding the TSAC;

[0051] e) optionally repeating steps (b), (c), and (d) with the newlibrary of (d); and

[0052] f) determining the nucleic acid sequence of the region encodingthe displayed peptide of a species from (d) and hence deducing thepeptide sequence.

[0053] The invention also provides a method of preparing a variegatednucleic acid library encoding Fn3 polypeptide monobodies having aplurality of nucleic acid species each comprising a plurality of loopregions, wherein the species encode a plurality of Fn3 β-strand domainsequences that are linked to a plurality of loop region sequences,wherein one or more of the loop region sequences vary by deletion,insertion or replacement of at least two amino acids from correspondingloop region sequences in wild-type Fn3, and wherein the β-strand domainsequences of the monobody have at least a 50% total amino acid sequencehomology to the corresponding amino acid sequences of β-strand domainsequences of the wild-type Fn3, comprising the steps of

[0054] a) preparing an Fn3 polypeptide monobody having a predeterminedsequence, wherein the polypeptide is capable of catalyzing a chemicalreaction with a catalyzed rate constant, k_(cat), and an uncatalyzedrate constant, k_(uncat), such that the ratio of k_(cat)/k_(uncat) isgreater than 10;

[0055] b) contacting the polypeptide with an immobilized or separabletransition state analog compound (TSAC) representing the approximatemolecular transition state of the chemical reaction;

[0056] c) determining the binding structure of the polypeptide:TSACcomplex by nuclear magnetic resonance spectroscopy or X-raycrystallography; and

[0057] d) preparing the variegated nucleic acid library, wherein thevariegation is performed at positions in the nucleic acid sequencewhich, from the information provided in (c), result in one or morepolypeptides with improved binding to or stabilization of the TSAC.

[0058] The invention also provides a kit for the performance of any ofthe methods of the invention. The invention further provides acomposition, e.g., a polypeptide, prepared by the use of the kit, oridentified by any of the methods of the invention.

[0059] The following abbreviations have been used in describing aminoacids, peptides, or proteins: Ala, or A, Alanine; Arg, or R, Arginine;Asn or N, asparagine; Asp, or D, aspartic acid; Cysor C, cystein; Gln,or Q, glutamine; Glu, or E, glutamic acid; Gly, or G, glycine; His, orH, histidine; IIe, or I, isoleucine; Leu, or L, leucine; Lys, or K,lysine; Met, or M, methionine; Phe, or F, phenylalanine; Pro, or P,proline; Ser, or S, serine; Thr, or T, threonine; Trp, or W, tryptophan;Tyr, or Y, tyrosine; Val, or V, valine.

[0060] The following abbreviations have been used in describing nucleicacids, DNA, or RNA: A, adenosine; T, thymidine; G, guanosine; C,cytosine.

BRIEF DESCRIPTION OF THE DRAWINGS

[0061]FIG. 1A. β-Strand and loop topology of anti-lysozymeimmunoglobulin D1.3. (Bhat et al., 1994). The locations ofcomplementarity determining regions (CDRs, hypervariable regions) areindicated.

[0062]FIG. 1B. β-Strand and loop topology of the 10th type III domain ofhuman fibronectin. (Main et al., 1992) The locations of theintegrin-binding Arg-Gly-Asp (RGD) sequence is indicated.

[0063]FIG. 1C. MOLSCRIPT representation of anti-lysozyme immunoglobulinD1.3. (Fraulis, 1991; Bhat et al., 1994) The locations ofcomplementarity determining regions (CDRs, hypervariable regions) areindicated.

[0064]FIG. 1D. MOLSCRIPT representation of the 10th type III domain ofhuman fibronectin. (Kraulis, 1991; Main et al., 1992) The locations ofthe integrin-binding Arg-Gly-Asp (RGD) sequence is indicated.

[0065]FIG. 2. Amino acid sequence (SEQ ID NO: 110) and restriction sitesof the synthetic Fn3 gene. The residue numbering is according to Main etal. (1992). Restriction enzyme sites designed are shown above the aminoacid sequence. β-Strands are denoted by underlines. The N-terminal “mq”sequence has been added for a subsequent cloning into an expressionvector. The His•tag (Novagen) fusion protein has an additional sequence,MGSSHHHHHHSSGLVPRGSH (SEQ ID NO:114), preceding the Fn3 sequence shownabove.

[0066]FIG. 3A. Far UV CD spectra of wild-type Fn3 at 25° C. and 90° C.Fn3 (50 μM) was dissolved in sodium acetate (50 mM, pH 4.6).

[0067]FIG. 3B. Thermal denaturation of Fn3 monitored at 215 nm.Temperature was increased at a rate of 1° C./min.

[0068]FIG. 4A. Cα trace of the crystal structure of the complex oflysozyme (HEL) and the Fv fragment of the anti-hen egg-white lysozyme(anti-HEL) antibody D1.3 (Bhat et al., 1994). Side chains of theresidues 99-102 of VH CDR3, which make contact with HEL, are also shown.

[0069]FIG. 4B. Contact surface area for each residue of the D1.3 VH-HELand VH-VL interactions plotted vs. residue number of D1.3 VH. Surfacearea and secondary structure were determined using the program DSSP(Kabsh and Sander, 1983).

[0070]FIG. 4C. Schematic drawings of the β-sheet structure of the Fstrand-loop-G strand moieties of D1.3 VH. The boxes denote residues inβ-strands and ovals those not in strands. The shaded boxes indicateresidues of which side chains are significantly buried. The broken linesindicate hydrogen bonds.

[0071]FIG. 4D. Schematic drawings of the β-sheet structure of the Fstrand-loop-G strand moieties of Fn3. The boxes denote residues inβ-strands and ovals those not in strands. The shaded boxes indicateresidues of which side chains are significantly buried. The broken linesindicate hydrogen bonds.

[0072]FIG. 5. Designed Fn3 gene showing DNA and amino acid sequences(SEQ ID NO:111 and SEQ ID NO:112). The amino acid numbering is accordingto Main et al. (1992). The two loops that were randomized incombinatorial libraries are enclosed in boxes.

[0073]FIG. 6. Map of plasmid pAS45. Plasmid pAS45 is the expressionvector of His•tag-Fn3.

[0074]FIG. 7. Map of plasmid pAS25. Plasmid pAS25 is the expressionvector of Fn3.

[0075]FIG. 8. Map of plasmid pAS38. pAS38 is a phagmid vector for thesurface display of Fn3.

[0076]FIG. 9. (Ubiquitin-1) Characterization of ligand-specific bindingof enriched clones using phage enzyme-linked immunosolvent assay(ELISA). Microtiter plate wells were coated with ubiquitin (1 μg/well;“Ligand (+)) and then blocked with BSA. Phage solution in TBS containingapproximately 10¹⁰ colony forming units (cfu) was added to a well andwashed with TBS. Bound phages were detected with anti-phage antibody-PODconjugate (Pharmacia) with Turbo-TMB (Pierce) as a substrate. Absorbancewas measured using a Molecular Devices SPECTRAMAX 250 microplatespectrophotometer. For a control, wells without the immobilized ligandwere used. 2-1 and 2-2 denote enriched clones from Library 2 eluted withfree ligand and acid, respectively. 4-1 and 4-2 denote enriched clonesfrom Library 4 eluted with free ligand and acid, respectively.

[0077]FIG. 10. (Ubiquitin-2) Competition phage ELISA of enriched clones.Phage solutions containing approximately 10¹⁰ cfu were first incubatedwith free ubiquitin at 4° C. for 1 hour prior to the binding to aligand-coated well. The wells were washed and phages detected asdescribed above.

[0078]FIG. 11. Competition phage ELISA of ubiquitin-binding monobody411. Experimental conditions are the same as described above forubiquitin. The ELISA was performed in the presence of free ubiquitin inthe binding solution. The experiments were performed with four differentpreparations of the same clone.

[0079]FIG. 12. (Fluorescein-1) Phage ELISA of four clones, pLB25.1(containing SEQ ID NO:115), pLB25.4 (containing SEQ ID NO:116), pLB24.1(containing SEQ ID NO:117) and pLB24.3 (containing SEQ ID NO:118).Experimental conditions are the same as ubiquitin-1 above.

[0080]FIG. 13. (Fluorescein-2) Competition ELISA of the four clones.Experimental conditions are the same as ubiquitin-2 above.

[0081]FIG. 14. ¹H, ¹⁵N-HSQC spectrum of a fluorescence-binding monobodyLB25.5. Approximately 20 μm protein was dissolved in 10 mm sodiumacetate buffer (pH 5.0) containing 100 mM sodium chloride. The spectrumwas collected at 30° C. on a Varian Unity INOVA 600 NMR spectrometer.

[0082]FIG. 15A. Characterization of the binding reaction of Ubi4-Fn3 tothe target, ubiquitin. Phage ELISA analysis of binding of Ubi4-Fn3 toubiquitin. The binding of Ubi4-phages to ubiquitin-coated wells wasmeasured. The control experiment was performed with wells containing noubiquitin.

[0083]FIG. 15B. Competition phage ELISA of Ubi4-Fn3. Ubi4-Fn3 phageswere preincubated with soluble ubiquitin at an indicated concentration,followed by the phage ELISA detection in ubiquitin-coated wells.

[0084]FIG. 15C. Competition phage ELISA testing the specificity of theUbi4 clone. The Ubi4 phages were preincubated with 250 μg/ml of solubleproteins, followed by phage ELISA as in (b).

[0085]FIG. 15D. ELISA using free proteins.

[0086]FIG. 16. Equilibrium unfolding curves for Ubi4-Fn3 (closedsymbols) and wild-type Fn3 (open symbols). Squares indicate datameasured in TBS (Tris HCI buffer (50 mM, pH 7.5) containing NaCl (150mM)). Circles indicate data measured in Gly HCl buffer (20 mM, pH 3.3)containing NaCl (300 mM). The curves show the best fit of the transitioncurve based on the two-state model. Parameters characterizing thetransitions are listed in Table 7.

[0087]FIG. 17. (a) ¹H, ¹⁵N-HSQC spectrum of [¹⁵N]-Ubi4-K Fn3. (b).Difference (δ_(wild-type)-δ_(Ubi4)) of ¹H (b) and ¹⁵N (c) chemicalshifts plotted versus residue number. Values for residues 82-84 (shownas filled circles) where Ubi4-K deletions are set to zero. Open circlesindicate residues that are mutated in the Ubi4-K protein. The locationsof β-strands are indicated with arrows.

DETAILED DESCRIPTION OF THE INVENTION

[0088] For the past decade the immune system has been exploited as arich source of de novo catalysts. Catalytic antibodies have been shownto have chemoselectivity, enantioselectivity, large rate accelerations,and even an ability to reroute chemical reactions. In most cases theantibodies have been elicited to transition state analog (TSA) haptens.These TSA haptens are stable, low-molecular weight compounds designed tomimic the structures of the energetically unstable transition statespecies that briefly (approximate half-life 10⁻¹³ s) appear alongreaction pathways between reactants and products. Anti-TSA antibodies,like natural enzymes, are thought to selectively bind and stabilizetransition state, thereby easing the passage of reactants to products.Thus, upon binding, the antibody lowers the energy of the actualtransition state and increases the rate of the reaction. These catalystscan be programmed to bind to geometrical and electrostatic features ofthe transition state so that the reaction route can be controlled byneutralizing unfavorable charges, overcoming entropic barriers, anddictating stereoelectronic features of the reaction. By this means evenreactions that are otherwise highly disfavored have been catalyzed(Janda et al. 1997). Further, in many instances catalysts have been madefor reactions for which there are no known natural or manmade enzymes.

[0089] The success of any combinatorial chemical system in obtaining aparticular function depends on the size of the library and the abilityto access its members. Most often the antibodies that are made in ananimal against a hapten that mimics the transition state of a reactionare first screened for binding to the hapten and then screened again forcatalytic activity. An improved method allows for the direct selectionfor catalysis from antibody libraries in phage, thereby linkingchemistry and replication.

[0090] A library of antibody fragments can be created on the surface offilamentous phage viruses by adding randomized antibody genes to thegene that encodes the phage's coat protein. Each phage then expressesand displays multiple copies of a single antibody fragment on itssurface. Because each phage possesses both the surface-displayedantibody fragment and the DNA that encodes that fragment, and antibodyfragment that binds to a target can be identified by amplifying theassociated DNA.

[0091] Immunochemists use as antigens materials that have as littlechemical reactivity as possible. It is almost always the case that onewishes the ultimate antibody to interact with native structures. Inreactive immunization the concept is just the opposite. One immunizeswith compounds that are highly reactive so that upon binding to theantibody molecule during the induction process, a chemical reactionensues. Later this same chemical reaction becomes part of the mechanismof the catalytic event. In a certain sense one is immunizing with achemical reaction rather than a substance per se. Reactive immunogenscan be considered as analogous to the mechanism-based inhibitors thatenzymologists use except that they are used in the inverse way in that,instead of inhibiting a mechanism, they induce a mechanism.

[0092] Man-made catalytic antibodies have considerable commercialpotential in many different applications. Catalytic antibody-basedproducts have been used successfully in prototype experiments intherapeutic applications, such as prodrug activation and cocaineinactivation, and in nontherapeutic applications, such as biosensors andorganic synthesis.

[0093] Catalytic antibodies are theoretically more attractive thannoncatalytic antibodies as therapeutic agents because, being catalytic,they may be used in lower doses, and also because their effects areunusually irreversible (for example, peptide bond cleavage rather thanbinding). In therapy, purified catalytic antibodies could be directlyadministered to a patient, or alternatively the patient's own catalyticantibody response could be elicited by immunization with an appropriatehapten. Catalytic antibodies also could be used as clinical diagnostictools or as regioselective or stereoselective catalysts in the synthesisof fine chemicals.

[0094] I. Mutation of Fn3 Loops and Grafting of Ab Loops onto Fn3

[0095] An ideal scaffold for CDR grafting is highly soluble and stable.It is small enough for structural analysis, yet large enough toaccommodate multiple CDRs so as to achieve tight binding and/or highspecificity.

[0096] A novel strategy to generate an artificial Ab system on theframework of an existing non-Ab protein was developed. An advantage ofthis approach over the minimization of an Ab scaffold is that one canavoid inheriting the undesired properties of Abs. Fibronectin type IIIdomain (Fn3) was used as the scaffold. Fibronectin is a large proteinwhich plays essential roles in the formation of extracellular matrix andcell-cell interactions; it consists of many repeats of three types (I,II and III) of small domains (Baron et al., 1991). Fn3 itself is theparadigm of a large subfamily (Fn3 family or s-type Ig family) of theimmunoglobulin superfamily (IgSF). The Fn3 family includes cell adhesionmolecules, cell surface hormone and cytokine receptors, chaperoning, andcarbohydrate-binding domains (for reviews, see Bork & Doolittle, 1992;Jones, 1993; Bork et al., 1994; Campbell & Spitzfaden, 1994; Harpez &Chothia, 1994).

[0097] Recently, crystallographic studies revealed that the structure ofthe DNA binding domains of the transcription factor NF-kB is alsoclosely related to the Fn3 fold (Ghosh et al., 1995; Müller et al.,1995). These proteins are all involved in specific molecularrecognition, and in most cases ligand-binding sites are formed bysurface loops, suggesting that the Fn3 scaffold is an excellentframework for building specific binding proteins. The 3D structure ofFn3 has been determined by NMR (Main et al., 1992) and by X-raycrystallography (Leahy et al., 1992; Dickinson et al., 1994). Thestructure is best described as a β-sandwich similar to that of Ab VHdomain except that Fn3 has seven β-strands instead of nine (FIG. 1).There are three loops on each end of Fn3; the positions of the BC, DEand FG loops approximately correspond to those of CDRI, 2 and 3 of theVH domain, respectively (FIGS. 1C, D).

[0098] Fn3 is small (˜95 residues), monomeric, soluble and stable. It isone of few members of IgSF that do not have disulfide bonds; VH has aninterstrand disulfide bond (FIG. 1A) and has marginal stability underreducing conditions. Fn3 has been expressed in E. coli (Aukhil et al.,1993). In addition, 17 Fn3 domains are present just in humanfibronectin, providing important information on conserved residues whichare often important for the stability and folding (for sequencealignment, see Main et al., 1992 and Dickinson et al., 1994). Fromsequence analysis, large variations are seen in the BC and FG loops,suggesting that the loops are not crucial to stability. NMR studies haverevealed that the FG loop is highly flexible; the flexibility has beenimplicated for the specific binding of the 10th Fn3 to α₅β₁ integrinthrough the Arg-Gly-Asp (RGD) (SEQ ID NO:113) motif. In the crystalstructure of human growth hormone-receptor complex (de Vos et al.,1992), the second Fn3 domain of the receptor interacts with hormone viathe FG and BC loops, suggesting it is feasible to build a binding siteusing the two loops.

[0099] The tenth type III module of fibronectin has a fold similar tothat of immunoglobulin domains, with seven P strands forming twoantiparallel β sheets, which pack against each other (Main et al.,1992). The structure of the type II module consists of seven β strands,which form a sandwich of two antiparallel β sheets, one containing threestrands (ABE) and the other four strands (C′CFG) (Williams et al.,1988). The triple-stranded β sheet consists of residues Glu-9-Thr-14(A), Ser-17-Asp-23 (B), and Thr-56-Ser-60 (E). The majority of theconserved residues contribute to the hydrophobic core, with theinvariant hydrophobic residues Trp-22 and Try-68 lying toward theN-terminal and C-terminal ends of the core, respectively. The β strandsare much less flexible and appear to provide a rigid framework uponwhich functional, flexible loops are built. The topology is similar tothat of immunoglobulin C domains.

[0100] Gene Construction and Mutagenesis

[0101] A synthetic gene for tenth Fn3 of human fibronectin (FIG. 2) wasdesigned which includes convenient restriction sites for ease ofmutagenesis and uses specific codons for high-level protein expression(Gribskov et al., 1984).

[0102] The gene was assembled as follows: (1) the gene sequence wasdivided into five parts with boundaries at designed restriction sites(FIG. 2); (2) for each part, a pair of oligonucleotides that codeopposite strands and have complementary overlaps of ˜15 bases wassynthesized; (3) the two oligonucleotides were annealed and singlestrand regions were filled in using the Klenow fragment of DNApolymerase; (4) the double-stranded oligonucleotide was cloned into thepET3a vector (Novagen) using restriction enzyme sites at the termini ofthe fragment and its sequence was confirmed by an Applied Biosystems DNAsequencer using the dideoxy termination protocol provided by themanufacturer; (5) steps 2-4 were repeated to obtain the whole gene(plasmid pAS25) (FIG. 7).

[0103] Although the present method takes more time to assemble a genethan the one-step polymerase chain reaction (PCR) method (Sandhu et al.,1992), no mutations occurred in the gene. Mutations would likely havebeen introduced by the low fidelity replication by Taq polymerase andwould have required time-consuming gene editing. The gene was alsocloned into the pET15b (Novagen) vector (pEW1). Both vectors expressedthe Fn3 gene under the control of bacteriophage T7 promoter (Studler etal. 1990); pAS25 expressed the 96-residue Fn3 protein only, while pEW1expressed Fn3 as a fusion protein with poly-histidine peptide (His•tag).Recombinant DNA manipulations were performed according to MolecularCloning (Sambrook et al., 1989), unless otherwise stated.

[0104] Mutations were introduced to the Fn3 gene using either cassettemutagenesis or oligonucleotide site-directed mutagenesis techniques(Deng & Nickoloff, 1992). Cassette mutagenesis was performed using thesame protocol for gene construction described above; double-stranded DNAfragment coding a new sequence was cloned into an expression vector(pAS25 and/or pEW1). Many mutations can be made by combining a newlysynthesized strand (coding mutations) and an oligonucleotide used forthe gene synthesis. The resulting genes were sequenced to confirm thatthe designed mutations and no other mutations were introduced bymutagenesis reactions.

[0105] Design and Synthesis of Fn3 Mutants with Antibody CDRs

[0106] Two candidate loops (FG and BC) were identified for grafting.Antibodies with known crystal structures were examined in order toidentify candidates for the sources of loops to be grafted onto Fn3.Anti-hen egg lysozyme (HEL) antibody D1.3 (Bhat et al., 1994) was chosenas the source of a CDR loop. The reasons for this choice were: (1) highresolution crystal structures of the free and complexed states areavailable (FIG. 4A; Bhat et al., 1994), (2) thermodynamics data for thebinding reaction are available (Tello et al., 1993), (3) D1.3 has beenused as a paradigm for Ab structural analysis and Ab engineering(Verhoeyen et al., 1988; McCafferty et al., 1990) (4) site-directedmutagenesis experiments have shown that CDR3 of the heavy chain(VH-CDR3) makes a larger contribution to the affinity than the otherCDRs (Hawkins et al., 1993), and (5) a binding assay can be easilyperformed. The objective for this trial was to graft VH-CDR3 of D1.3onto the Fn3 scaffold without significant loss of stability.

[0107] An analysis of the D1.3 structure (FIG. 4) revealed that onlyresidues 99-102 (“RDYR”) make direct contact with hen egg-white lysozyme(HEL) (FIG. 4B), although VH-CDR3 is defined as longer (Bhat et al.,1994). It should be noted that the C-terminal half of VH-CDR3 (residues101-104) made significant contact with the VL domain (FIG. 4B). It hasalso become clear that D1.3 VH-CDR3 (FIG. 4C) has a shorter turn betweenthe strands F and G than the FG loop of Fn3 (FIG. 4D). Therefore, mutantsequences were designed by using the RDYR (99-102) of D1.3 as the coreand made different boundaries and loop lengths (Table 1). Shorter loopsmay mimic the D1.3 CDR3 conformation better, thereby yielding higheraffinity, but they may also significantly reduce stability by removingwild-type interactions of Fn3. TABLE 1 Amino acid sequences of D 1.3 VHCDR3, VH8 CDR3 and Fn3 FG loop and list of planned mutants. (SEQ IDNO:1) 96     100         105 •       •           • D1.3 A  R  E R D Y RL  D  Y W G Q G (SEQ ID NO:2) VH8 A  R  G A V V S Y Y A M  D  Y  W G Q G(SEQ ID NO:3)      75       80        85       •        •        • Fn3 Y A  V T G R G D S P A S S K P I Mutant Sequence (SEQ ID NO:4) D1.3-1 Y AE R D Y R L D Y - - - - P I (SEQ ID NO:5) D1.3-2 Y A V R D Y R L DY - - - - P I (SEQ ID NO:6) D1.3-3 Y A V R D Y R L D Y A S S K P I (SEQID NO:7) D1.3-4 Y A V R D Y R L D Y - - - K P I (SEQ ID NO:8) D1.3-5 Y AV R D Y R - - - - - S K P I (SEQ ID NO:9) D1.3-6 Y A V T R D Y R L - - SS K P I (SEQ ID NO:10) D1.3-7 Y A V T E R D Y R L - S S K P I (SEQ IDNO:11) VH8-1 Y A V A V V S Y Y A M D Y - P I (SEQ ID NO:12) VH8-2 Y A VT A V V S Y Y A S S K P I

[0108] Underlines indicate residues in β-strands. Bold charactersindicate replaced residues.

[0109] In addition, an anti-HEL single VH domain termed VH8 (Ward etal., 1989) was chosen as a template. VH8 was selected by libraryscreening and, in spite of the lack of the VL domain, VH8 has anaffinity for HEL of 27 nM, probably due to its longer VH-CDR3 (Table 1).Therefore, its VH-CDR3 was grafted onto Fn3. Longer loops may beadvantageous on the Fn3 framework because they may provide higheraffinity and also are close to the loop length of wild-type Fn3. The 3Dstructure of VH8 was not known and thus the VH8 CDR3 sequence wasaligned with that of D1.3 VH-CDR3; two loops were designed (Table 1).

[0110] Mutant Construction and Production

[0111] Site-directed mutagenesis experiments were performed to obtaindesigned sequences. Two mutant Fn3s, D1.3-1 and D1.3-4 (Table 1) wereobtained and both were expressed as soluble His-tag fusion proteins.D1.34 was purified and the His.tag portion was removed by thrombincleavage. D1.3-4 is soluble up to at least 1 mM at pH 7.2. Noaggregation of the protein has been observed during sample preparationand NMR data acquisition.

[0112] Protein Expression and Purification

[0113]E. coli BL21 (DE3) (Novagen) were transformed with an expressionvector (pAS25, pEW1 and their derivatives) containing a gene for thewild-type or a mutant. Cells were grown in M9 minimal medium and M9medium supplemented with Bactotrypton (Difco) containing ampicillin (200μg/ml). For isotopic labeling, ¹⁵N NH⁴CI and/or ¹³C glucose replacedunlabeled components. 500 mL medium in a 2 liter baffle flask wereinoculated with 10 ml of overnight culture and agitated at 37° C.Isopropylthio-β-galactoside (IPTG) was added at a final concentration of1 mM to initiate protein expression when OD (600 nm) reaches one. Theceils were harvested by centrifugation 3 hours after the addition ofIPTG and kept frozen at −70° C. until used.

[0114] Fn3 without His•tag was purified as follows. Cells were suspendedin 5 ml/(g cell) of Tris (50 mM, pH 7.6) containingethylenediaminetetraacetic acid (EDTA; 1 mM) and phenylmethylsulfonylfluoride (1 mM). HEL was added to a final concentration of 0.5 mg/ml.After incubating the solution for 30 minutes at 37° C., it was sonicatedthree times for 30 seconds on ice. Cell debris was removed bycentrifugation. Ammonium sulfate was added to the solution andprecipitate recovered by centrifugation. The pellet was dissolved in5-10 ml sodium acetate (50 mM, pH 4.6) and insoluble material wasremoved by centrifugation. The solution was applied to a SEPHACRYLS100HR column (Pharmacia) equilibrated in the sodium acetate buffer.Fractions containing Fn3 then was applied to a RESOURCES® column(Pharmacia) equilibrated in sodium acetate (50 mM, pH 4.6) and elutedwith a linear gradient of sodium chloride (0-0.5 M). The protocol can beadjusted to purify mutant proteins with different surface chargeproperties.

[0115] Fn3 with His•tag was purified as follows. The soluble fractionwas prepared as described above, except that sodium phosphate buffer (50mM, pH 7.6) containing sodium chloride (100 mM) replaced the Trisbuffer. The solution was applied to a HI-TRAP chelating column(Pharmacia) preloaded with nickel and equilibrated in the phosphatebuffer. After washing the column with the buffer, His•tag-Fn3 was elutedin the phosphate buffer containing 50 mM EDTA. Fractions containingHis•tag-Fn3 were pooled and applied to a SEPHACRYL S100-HR column,yielding highly pure protein. The His•tag portion was cleaved off bytreating the fusion protein with thrombin using the protocol supplied byNovagen. Fn3 was separated from the His•tag peptide and thrombin by aRESOURCES® column using the protocol above.

[0116] The wild-type and two mutant proteins so far examined areexpressed as soluble proteins. In the case that a mutant is expressed asinclusion bodies (insoluble aggregate), it is first examined if it canbe expressed as a soluble protein at lower temperature (e.g., 25-30°C.). If this is not possible, the inclusion bodies are collected bylow-speed centrifugation following cell lysis as described above. Thepellet is washed with buffer, sonicated and centrifuged. The inclusionbodies are solubilized in phosphate buffer (50 mM, pH 7.6) containingguanidinium chloride (GdnCl, 6 M) and will be loaded on a HI-TRAPchelating column. The protein is eluted with the buffer containing GdnCland 50 mM EDTA.

[0117] Conformation of Mutant Fn3, D1.3-4

[0118] The ¹H NMR spectra of His•tag D1.3-4 fusion protein closelyresembled that of the wild-type, suggesting the mutant is folded in asimilar conformation to that of the wild-type. The spectrum of D1.3-4after the removal of the His•tag peptide showed a large spectraldispersion. A large dispersion of amide protons (7-9.5 ppm) and a largenumber of downfield (5.0-6.5 ppm) C^(α) protons are characteristic of aβ-sheet protein (Wüthrich, 1986).

[0119] The 2D NOESY spectrum of D1.34 provided further evidence for apreserved conformation. The region in the spectrum showed interactionsbetween upfield methyl protons (<0.5 ppm) and methyl-methylene protons.The Va172 γ methyl resonances were well separated in the wild-typespectrum (−0.07 and 0.37 ppm; (Baron et al., 1992)). Resonancescorresponding to the two methyl protons are present in the D1.3-4spectrum (−0.07 and 0.44 ppm). The cross peak between these tworesonances and other conserved cross peaks indicate that the tworesonances in the D1.3-4 spectrum are highly likely those of Va172 andthat other methyl protons are in nearly identical environment to that ofwild-type Fn3. Minor differences between the two spectra are presumablydue to small structural perturbation due to the mutations. Va172 is onthe F strand, where it forms a part of the central hydrophobic core ofFn3 (Main et al., 1992). It is only four residues away from the mutatedresidues of the FG loop (Table 1). The results are remarkable because,despite there being 7 mutations and 3 deletions in the loop (more than10% of total residues; FIG. 12, Table 2), D1.3-4 retains a 3D structurevirtually identical to that of the wild-type (except for the mutatedloop). Therefore, the results provide strong support that the FG loop isnot significantly contributing to the folding and stability of the Fn3molecule and thus that the FG loop can be mutated extensively. TABLE 2!Sequences of oligonucleotides? !Name? Sequence (SEQ ID NO:13) FN1FCGGGATCCCATATGCAGGTTTCTGATGTTCCGCGTGACC TGGAAGTTGTTGCTGCGACC (SEQ IDNO:14) FN1R TAACTGCAGGAGCATCCCAGCTGATCAGCAGGCTAGTCG GGGTCGCAGCAACAAC(SEQ ID NO:15) FN2F CTCCTGCAGTTACCGTGCGTTATTACCGTATCACGTACG GTGAAACCGGTG(SEQ ID NO:16) FN2R GTGAATTCCTGAACCGGGGAGTTACCACCGGTTTCACCG (SEQ IDNO:17) FN3F AGGAATTCACTGTACCTGGTTCCAAGTCTACTGCTACCA TCAGCGG (SEQ IDNO:18) FN3R GTATAGTCGACACCCGGTTTCAGGCCGCTGATGGTAGC (SEQ ID NO:19) FN4FCGGGTGTCGACTATACCATCACTGTATACGCT (SEQ ID NO:20) FN4RCGGGATCCGAGCTCGCTGGGCTGTCACCACGGCCAGTAA CAGCGTATACAGTGAT (SEQ ID NO:21)FN5F CAGCGAGCTCCAAGCCAATCTCGATTAACTACCGT (SEQ ID NO:22) FN5RCGGGATCCTCGAGTTACTAGGTACGGTAGTTAATCGA (SEQ ID NO:23) FN5RCGGGATCCACGCGTGCCACCGGTACGGTAGTTAATCGA (SEQ ID NO:24) gene3FCGGGATCCACGCGTCCATTCGTTTGTGAATATCAAGGCC AATCG (SEQ ID NO:25) gene3RCCGGAAGCTTTAAGACTCCTTATTACGCAGTATGTTAGC (SEQ ID NO:26) 38TAABg1IICTGTTACTGGCCGTGAGATCTAACCAGCGAGCTCCA (SEQ ID NO:27) BC3GATCAGCTGGGATGCTCCTNNKNNKNNKNNKNNKTATTA CCGTATCACGTA (SEQ ID NO:28) FG2TGTATACGCTGTTACTGGCNNKNNKNNKNNKNNKNNKNN KTCCAAGCCAATCTCGAT (SEQ IDNO:29) FG3 CTGTATACGCTGTTACTGGCNNKNNKNNKNNKCCAGCGA GCTCCAAG (SEQ IDNO:30) FG4 CATCACTGTATACGCTGTTACTNNKNNKNNKNNKNNKTC CAAGCCAATCTC

[0120] Restriction enzyme sites are underlined. N and K denote anequimolar mixture of A, T. G and C and that of G and T, respectively.

[0121] Structure and Stability Measurements

[0122] Structures of Abs were analyzed using quantitative methods (e.g.,DSSP (Kabsch & Sander, 1983) and PDBFIT (D. McRee, The Scripps ResearchInstitute)) as well as computer graphics (e.g., QUANTA (MolecularSimulations) and WHAT IF (G. Vriend, European Molecular BiologyLaboratory)) to superimpose the strand-loop-strand structures of Abs andFn3.

[0123] The stability of FnAbs was determined by measuring temperature-and chemical denaturant-induced unfolding reactions (Pace et al., 1989).The temperature-induced unfolding reaction was measured using a circulardichroism (CD) polarimeter. Ellipticity at 222 and 215 nm was recordedas the sample temperature was slowly raised. Sample concentrationsbetween 10 and 50 μM were used. After the unfolding baseline wasestablished, the temperature was lowered to examine the reversibility ofthe unfolding reaction. Free energy of unfolding was determined byfitting data to the equation for the two-state transition (Becktel &Schellman, 1987; Pace et al., 1989). Nonlinear least-squares fitting wasperformed using the program IGOR (WaveMetrics) on a Macintosh computer.

[0124] The structure and stability of two selected mutant Fn3s werestudied; the first mutant was D1.34 (Table 2) and the second was amutant called AS40 which contains four mutations in the BC loop(A²⁶V²⁷T²⁸V²⁹)→TQRQ). AS40 was randomly chosen from the BC loop librarydescribed above. Both mutants were expressed as soluble proteins in E.coli and were concentrated at least to 1 mM, permitting NMR studies.

[0125] The mid-point of the thermal denaturation for both mutants wasapproximately 69° C., as compared to approximately 79° C. for thewild-type protein. The results indicated that the extensive mutations atthe two surface loops did not drastically decrease the stability of Fn3,and thus demonstrated the feasibility of introducing a large number ofmutations in both loops.

[0126] Stability was also determined by guanidinium chloride (GdnCl)-and urea-induced unfolding reactions. Preliminary unfolding curves wererecorded using a fluorometer equipped with a motor-driven syringe; GdnClor urea were added continuously to the protein solution in the cuvette.Based on the preliminary unfolding curves, separate samples containingvarying concentration of a denaturant were prepared and fluorescence(excitation at 290 nm, emission at 300-400 nm) or CD (ellipticity at 222and 215 nm) were measured after the samples were equilibrated at themeasurement temperature for at least one hour. The curve was fitted bythe least-squares method to the equation for the two-state model(Santoro & Bolen, 1988; Koide et al., 1993). The change in proteinconcentration was compensated if required.

[0127] Once the reversibility of the thermal unfolding reaction isestablished, the unfolding reaction is measured by a Microcal MC-2differential scanning calorimeter (DSC). The cell (˜1.3 ml) will befilled with FnAb solution (0.1-1 mM) and ΔCp(=ΔH/ΔT) will be recorded asthe temperature is slowly raised. T_(m) (the midpoint of unfolding), ΔHof unfolding and ΔG of unfolding is determined by fitting the transitioncurve (Privalov & Potekhin, 1986) with the ORIGIN software provided byMicrocal.

[0128] Thermal Unfolding

[0129] A temperature-induced unfolding experiment on Fn3 was performedusing circular dichroism (CD) spectroscopy to monitor changes insecondary structure. The CD spectrum of the native Fn3 shows a weaksignal near 222 nm (FIG. 3A), consistent with the predominantlyβ-structure of Fn3 (Perczel et al., 1992). A cooperative unfoldingtransition is observed at 80-90° C., clearly indicating high stabilityof Fn3 (FIG. 3B). The free energy of unfolding could not be determineddue to the lack of a post-transition baseline. The result is consistentwith the high stability of the first Fn3 domain of human fibronectin(Litvinovich et al., 1992), thus indicating that Fn3 domains are ingeneral highly stable.

[0130] Binding Assays

[0131] Binding reaction of FnAbs were characterized quantitatively usingan isothermal titration calorimeter (ITC) and fluorescence spectroscopy.

[0132] The enthalpy change (ΔH) of binding were measured using aMicrocal OMEGA ITC (Wiseman et al., 1989). The sample cell (˜1.3 ml) wasfilled with FnAbs solution (≦100 μM, changed according to K_(d)), andthe reference cell filled with distilled water; the system wasequilibrated at a given temperature until a stable baseline is obtained;5-20 μl of ligand solution (≦2 mM) was injected by a motordriven syringewithin a short duration (20 sec) followed by an equilibration delay (4minutes); the injection was repeated and heat generation/absorption foreach injection was measured. From the change in the observed heat changeas a function of ligand concentration, ΔH and K_(d) was determined(Wiseman et al., 1989). ΔG and ΔS of the binding reaction was deducedfrom the two directly measured parameters. Deviation from thetheoretical curve was examined to assess nonspecific (multiplesite)binding. Experiments were also performed by placing a ligand in the celland titrating with an FnAb. It should be emphasized that only ITC givesdirect measurement of ΔH, thereby making it possible to evaluateenthalpic and entropic contributions to the binding energy. ITC wassuccessfully used to monitor the binding reaction of the D1.3 Ab (Telloet al., 1993; Bhat et al., 1994).

[0133] Intrinsic fluorescence is monitored to measure binding reactionswith K_(d) in the sub-μM range where the determination of K_(d) by ITCis difficult. Trp fluorescence (excitation at ˜290 nm, emission at300-350 nm) and Tyr fluorescence (excitation at ˜260 nm, emission at˜303 nm) is monitored as the Fn3-mutant solution (≦10 μM) is titratedwith ligand solution (≦100 μM). K_(d) of the reaction is determined bythe nonlinear least-squares fitting of the bimolecular binding equation.Presence of secondary binding sites is examined using Scatchardanalysis. In all binding assays, control experiments are performedbusing wild-type Fn3 (or unrelated FnAbs) in place of FnAbs of interest.

[0134] II. Production of Fn3 Mutants with High Affinity and SpecificityFnAbs

[0135] Library screening was carried out in order to select FnAbs whichbind to specific ligands. This is complementary to the modeling approachdescribed above. The advantage of combinatorial screening is that onecan easily produce and screen a large number of variants (≧10⁸), whichis not feasible with specific mutagenesis (“rational design”)approaches. The phage display technique (Smith, 1985; O'Neil & Hoess,1995) was used to effect the screening processes. Fn3 was fused to aphage coat protein (pHI) and displayed on the surface of filamentousphages. These phages harbor a single-stranded DNA genome that containsthe gene coding the Fn3 fusion protein. The amino acid sequence ofdefined regions of Fn3 were randomized using a degenerate nucleotidesequence, thereby constructing a library. Phages displaying Fn3 mutantswith desired binding capabilities were selected in vitro, recovered andamplified. The amino acid sequence of a selected clone can be identifiedreadily by sequencing the Fn3 gene of the selected phage. The protocolsof Smith (Smith & Scott, 1993) were followed with minor modifications.

[0136] The objective was to produce FnAbs which have high affinity tosmall protein ligands. HEL and the B1 domain of staphylococcal protein G(hereafter referred to as protein G) were used as ligands. Protein G issmall (56 amino acids) and highly stable (Minor & Kim, 1994; Smith etal., 1994). Its structure was determined by NMR spectroscopy (Gronenbomet al., 1991) to be a helix packed against a four-strand β-sheet. Theresulting FnAb-protein G complexes (˜150 residues) is one of thesmallest protein-protein complexes produced to date, well within therange of direct NMR methods. The small size, the high stability andsolubility of both components and the ability to label each with stableisotopes (¹³C and ¹⁵N; see below for protein G) make the complexes anideal model system for NMR studies on protein-protein interactions.

[0137] The successful loop replacement of Fn3 (the mutant D1.34)demonstrate that at least ten residues can be mutated without the lossof the global fold. Based on this, a library was first constructed inwhich only residues in the FG loop are randomized. After results of loopreplacement experiments on the BC loop were obtained, mutation siteswere extended that include the BC loop and other sites.

[0138] Construction of Fn3 Phage Display System

[0139] An M13 phage-based expression vector pASM1 has been constructedas follows: an oligonucleotide coding the signal peptide of OmpT wascloned at the 5′ end of the Fn3 gene; a gene fragment coding theC-terminal domain of M13 pIII was prepared from the wild-type gene IIIgene of M13 mp18 using PCR (Corey et al., 1993) and the fragment wasinserted at the 3′ end of the OmpT-Fn3 gene; a spacer sequence has beeninserted between Fn3 and pIII. The resultant fragment (OmpTFn3-pIII) wascloned in the multiple cloning site of M13 mp18, where the fusion geneis under the control of the lac promoter. This system will produce theFn3-pIII fusion protein as well as the wild-type pIII protein. Theco-expression of wild-type pIII is expected to reduce the number offusion pIII protein, thereby increasing the phage infectivity (Corey etal., 1993) (five copies of pIII are present on a phage particle). Inaddition, a smaller number of fusion pIII protein may be advantageous inselecting tight binding proteins, because the chelating effect due tomultiple binding sites should be smaller than that with all five copiesof fusion pIII (Bass et al., 1990). This system has successfullydisplayed the serine protease trypsin (Corey et al., 1993). Phages wereproduced and purified using E. coli K91kan (Smith & Scott, 1993)according to a standard method (Sambrook et al., 1989) except that phageparticles were purified by a second polyethylene glycol precipitationand acid precipitation.

[0140] Successful display of Fn3 on fusion phages has been confirmed byELISA using an Ab against fibronectin (Sigma), clearly indicating thatit is feasible to construct libraries using this system.

[0141] An alternative system using the fUSE5 (Parmley & Smith, 1988) mayalso be used. The Fn3 gene is inserted to fUSE5 using the SfiIrestriction sites introduced at the 5′- and 3′- ends of the Fn3 genePCR. This system displays only the fusion pIII protein (up to fivecopies) on the surface of a phage. Phages are produced and purified asdescribed (Smith & Scott, 1993). This system has been used to displaymany proteins and is robust. The advantage of fUSE5 is its low toxicity.This is due to the low copy number of the replication form (RF) in thehost, which in turn makes it difficult to prepare a sufficient amount ofRF for library construction (Smith & Scott, 1993).

[0142] Construction of Libraries

[0143] The first library was constructed of the Fn3 domain displayed onthe surface of MB phage in which seven residues (77-83) in the FG loop(FIG. 4D) were randomized. Randomization will be achieved by the use ofan oligonucleotide containing degenerated nucleotide sequence. Adouble-stranded nucleotide was prepared by the same protocol as for genesynthesis (see above) except that one strand had an (NNK)₆(NNG) sequenceat the mutation sites, where N corresponds to an equimolar mixture of A,T, G and C and K corresponds to an equimolar mixture of G and T. The(NNG) codon at residue 83 was required to conserve the SacI restrictionsite (FIG. 2). The (NNK) codon codes all of the 20 amino acids, whilethe NNG codon codes 14. Therefore, this library contained ˜10⁹independent sequences. The library was constructed by ligating thedouble-stranded nucleotide into the wild-type phage vector, pASM1, andthe transfecting E. coli XL1 blue (Stratagene) using electroporation.XL1 blue has the lacI^(q) phenotype and thus suppresses the expressionof the Fn3-pIII fusion protein in the absence of lac inducers. Theinitial library was propagated in this way, to avoid selection againsttoxic Fn3-pIII clones. Phages displaying the randomized Fn3-pIII fusionprotein were prepared by propagating phages with K91kan as the host.K91kan does not suppress the production of the fusion protein, becauseit does not have lacI^(q). Another library was also generated in whichthe BC loop (residues 26-20) was randomized.

[0144] Selection of Displayed FnAbs

[0145] Screening of Fn3 phage libraries was performed using thebiopanning protocol (Smith & Scott, 1993); a ligand is biotinylated andthe strong biotinstreptavidin interaction was used to immobilize theligand on a streptavidin-coated dish. Experiments were performed at roomtemperature (˜22° C.). For the initial recovery of phages from alibrary, 10 μg of a biotinylated ligand were immobilized on astreptavidin-coated polystyrene dish (35 mm, Falcon 1008) and then aphage solution (containing ˜10¹¹ pfu (plaque-forming unit)) was added.After washing the dish with an appropriate buffer (typically TBST,Tris-HCl (50 mM, pH 7.5), NaCl (150 mM) and Tween 20 (0.5%)), boundphages were eluted by one or combinations of the following conditions:low pH, an addition of a free ligand, urea (up to 6 M) and, in the caseof anti-protein G FnAbs, cleaving the protein G-biotin linker bythrombin. Recovered phages were amplified using the standard protocolusing K91kan as the host (Sambrook et al., 1989). The selection processwere repeated 3-5 times to concentrate positive clones. From the secondround on, the amount of the ligand were gradually decreased (to ˜1 μg)and the biotinylated ligand were mixed with a phage solution beforetransferring a dish (G. P. Smith, personal communication). After thefinal round, 10-20 clones were picked, and their DNA sequence will bedetermined. The ligand affinity of the clones were measured first by thephage-ELISA method (see below).

[0146] To suppress potential binding of the Fn3 framework (backgroundbinding) to a ligand, wild-type Fn3 may be added as a competitor in thebuffers. In addition, unrelated proteins (e.g., bovine serum albumin,cytochrome c and RNase A) may be used as competitors to select highlyspecific FnAbs.

[0147] Binding Assay

[0148] The binding affinity of FnAbs on phage surface is characterizedsemiquantitatively using the phage ELISA technique (Li et al., 1995).Wells of microtiter plates (Nunc) are coated with a ligand protein (orwith streptavidin followed by the binding of a biotinylated ligand) andblocked with the BLOTTO solution (Pierce). Purified phages (˜10¹⁰ pfu)originating from single plaques (M13)/colonies (fUSE5) are added to eachwell and incubated overnight at 4° C. After washing wells with anappropriate buffer (see above), bound phages are detected by thestandard ELISA protocol using anti-M13 Ab (rabbit, Sigma) andanti-rabbit Ig-peroxidase conjugate (Pierce) or using anti-M13Ab-peroxidase conjugate (Pharmacia). Colormetric assays are performedusing TMB (3,3′,5,5′-tetramethylbenzidine, Pierce). The high affinity ofprotein G to immunoglobulins present a special problem; Abs cannot beused in detection. Therefore, to detect anti-protein G FnAbs, fusionphages are immobilized in wells and the binding is then measured usingbiotinylated protein G followed by the detection usingstreptavidin-peroxidase conjugate.

[0149] Production of Soluble FnAbs

[0150] After preliminary characterization of mutant Fn3s using phageELISA, mutant genes are subcloned into the expression vector pEW1.Mutant proteins are produced as His•tag fusion proteins and purified,and their conformation, stability and ligand affinity are characterized.

[0151] Thus, Fn3 is the fourth example of a monomericimmunoglobulin-like scaffold that can be used for engineering bindingproteins. Successful selection of novel binding proteins have also beenbased on minibody, tendamistat and “camelized” immunoglobulin VH domainscaffolds (Martin et al., 1994; Davies & Riechmann, 1995; McConnell &Hoess, 1995). The Fn3 scaffold has advantages over these systems.Bianchi et al. reported that the stability of a minibody was 2.5kcal/mol, significantly lower than that of Ubi4-K. No detailedstructural characterization of minibodies has been reported to date.Tendamistat and the VH domain contain disulfide bonds, and thuspreparation of correctly folded proteins may be difficult. Davies andRiechmann reported that the yields of their camelized VH domains wereless than 1 mg per liter culture (Davies & Riechmann, 1996).

[0152] Thus, the Fn3 framework can be used as a scaffold for molecularrecognition. Its small size, stability and well-characterized structuremake Fn3 an attractive system. In light of the ubiquitous presence ofFn3 in a wide variety of natural proteins involved in ligand binding,one can engineer Fn3-based binding proteins to different classes oftargets.

[0153] The following examples are intended to illustrate but not limitthe invention.

EXAMPLE I Construction of the Fn3 Gene

[0154] A synthetic gene for tenth Fn3 of fibronectin (FIG. 1) wasdesigned on the basis of amino acid residue 1416-1509 of humanfibronectin (Kornblihtt, et al., 1985) and its three dimensionalstructure (Main, et al., 1992). The gene was engineered to includeconvenient restriction sites for mutagenesis and the so-called“preferred codons” for high level protein expression (Gribskov, et al.,1984) were used. In addition, a glutamine residue was inserted after theN-terminal methionine in order to avoid partial processing of theN-terminal methionine which often degrades NMR spectra (Smith, et al.,1994). Chemical reagents were of the analytical grade or better andpurchased from Sigma Chemical Company and J. T. Baker, unless otherwisenoted. Recombinant DNA procedures were performed as described in“Molecular Cloning” (Sambrook, et al., 1989), unless otherwise stated.Custom oligonucleotides were purchased from Operon Technologies.Restriction and modification enzymes were from New England Biolabs.

[0155] The gene was assembled in the following manner. First, the genesequence (FIG. 5) was divided into five parts with boundaries atdesigned restriction sites: fragment 1, NdeI-PstI (oligonucleotides FN1F and FN1R (Table 2); fragment 2, PstI-EcoRI (FN2F and FN2R); fragment3, EcoRI-SalI (FN3F and FN3R); fragment 4, SalI-SacI (FN4F and FN4R);fragment 5, SacI-BamHI (FN5F and FN5R). Second, for each part, a pair ofoligonucleotides which code opposite strands and have complementaryoverlaps of approximately 15 bases was synthesized. Theseoligonucleotides were designated FN1F-FN5R and are shown in Table 2.Third, each pair (e.g., FN1F and FN1R) was annealed and single-strandregions were filled in using the Klenow fragment of DNA polymerase.Fourth, the double stranded oligonucleotide was digested with therelevant restriction enzymes at the termini of the fragment and clonedinto the PBLUESCRIPT SK plasmid (Stratagene) which had been digestedwith the same enzymes as those used for the fragments. The DNA sequenceof the inserted fragment was confirmed by DNA sequencing using anApplied Biosystems DNA sequencer and the dideoxy termination protocolprovided by the manufacturer. Last, steps 2-4 were repeated to obtainthe entire gene.

[0156] The gene was also cloned into the pET3a and pET15b (Novagen)vectors (pAS45 and pAS25, respectively). The maps of the plasmids areshown in FIGS. 6 and 7. E. coli BL21 (DE3) (Novagen) containing thesevectors expressed the Fn3 gene under the control of bacteriophage T7promotor (Studier, et al., 1990); pAS24 expresses the 96-residue Fn3protein only, while pAS45 expresses Fn3 as a fusion protein withpoly-histidine peptide (His•tag). High level expression of the Fn3protein and its derivatives in E. coli was detected as an intense bandon SDS-PAGE stained with CBB.

[0157] The binding reaction of the monobodies is characterizedquantitatively by means of fluorescence spectroscopy using purifiedsoluble monobodies.

[0158] Intrinsic fluorescence is monitored to measure binding reactions.Trp fluorescence (excitation at ˜290 nm, emission at 300 350 nm) and Tyrfluorescence (excitation at ˜260 nm, emission at ˜303 nm) is monitoredas the Fn3-mutant solution (≦100 μM) is titrated with a ligand solution.When a ligand is fluorescent (e.g. fluorescein), fluorescence from theligand may be used. K_(d) of the reaction will be determined by thenonlinear least-squares fitting of the bimolecular binding equation.

[0159] If intrinsic fluorescence cannot be used to monitor the bindingreaction, monobodies are labeled with fluorescein-NHS (Pierce) andfluorescence polarization is used to monitor the binding reaction (Burkeet al., 1996).

EXAMPLE II Modifications to Include Restriction Sites in the Fn3 Gene

[0160] The restriction sites were incorporated in the synthetic Fn3 genewithout changing the amino acid sequence Fn3. The positions of therestriction sites were chosen so that the gene construction could becompleted without synthesizing long (>60 bases) oligonucleotides and sothat two loop regions could be mutated (including by randomization) bythe cassette mutagenesis method (i.e., swapping a fragment with anothersynthetic fragment containing mutations). In addition, the restrictionsites were chosen so that most sites were unique in the vector for phagedisplay. Unique restriction sites allow one to recombine monobody cloneswhich have been already selected in order to supply a larger sequencespace.

EXAMPLE III Construction of M13 Phage Display Libraries

[0161] A vector for phage display, pAS38 (for its map, see FIG. 8) wasconstructed as follows. The XbaI-BamHI fragment of pET12a encoding thesignal peptide of OmpT was cloned at the 5′ end of the Fn3 gene. TheC-terminal region (from the FN5F and FN5R′ oligonucleotides, see Table2) of the Fn3 gene was replaced with a new fragment consisting of theFN5F and FN5R′ oligonucleotides (Table 2) which introduced a MluI siteand a linker sequence for making a fusion protein with the pIII proteinof bacteriophage M13. A gene fragment coding the C-terminal domain ofM13 pIII was prepared from the wild-type gene III of M13mp18 using PCR(Corey, et al., 1993) and the fragment was inserted at the 3′ end of theOmpT-Fn3 fusion gene using the MluI and HindIII sites.

[0162] Phages were produced and purified using a helper phage, M13K07,according to a standard method (Sambrook, et al., 1989) except thatphage particles were purified by a second polyethylene glycolprecipitation. Successful display of Fn3 on fusion phages was confirmedby ELISA (Harlow & Lane, 1988) using an antibody against fibronectin(Sigma) and a custom anti-FN3 antibody (Cocalico Biologicals, PA., USA).

EXAMPLE IV Libraries Containing Loop Variegations in the AB Loop

[0163] A nucleic acid phage display library having variegation in the ABloop is prepared by the following methods. Randomization is achieved bythe use of oligonucleotides containing degenerated nucleotide sequence.Residues to be variegated are identified by examining the X-ray and NMRstructures of Fn3 (Protein Data Bank accession numbers, 1FNA and 1TTF,respectively). Oligonucleotides containing NNK (N and K here denote anequimolar mixture of A, T, G, and C and an equimolar mixture of G and T,respectively) for the variegated residues are synthesized (seeoligonucleotides BC3, FG2, FG3, and FG4 in Table 2 for example). The NNKmixture codes for all twenty amino acids and one termination codon(TAG). TAG, however, is suppressed in the E. coli XL-1 blue.Single-stranded DNAs of pAS38 (and its derivatives) are prepared using astandard protocol (Sambrook, et al., 1989).

[0164] Site-directed mutagenesis is performed following publishedmethods (see for example, Kunkel, 1985) using a MUTA-GENE kit (BioRad).The libraries are constructed by electroporation of E. coli XL-1 Blueelectroporation competent cells (200 μl; Stratagene) with 1 μg of theplasmid DNA using a BTX electrocell manipulator ECM 395 1 mm gapcuvette. A portion of the transformed cells is plated on an LB-agarplate containing ampicillin (100 μg/ml) to determine the transformationefficiency. Typically, 3×10⁸ transformants are obtained with 1 μg ofDNA, and thus a library contains 10⁸ to 10⁹ independent clones. Phagemidparticles were prepared as described above.

EXAMPLE V Loop Variegations in the BC, CD, DE, EF or FG Loop

[0165] A nucleic acid phage display library having five variegatedresidues (residues number 26-30) in the BC loop, and one having sevenvariegated residues (residue numbers 78-84) in the FG loop, was preparedusing the methods described in Example IV above. Other nucleic acidphage display libraries having variegation in the CD, DE or EF loop canbe prepared by similar methods.

EXAMPLE VI Loop Variegations in the FG and BC Loop

[0166] A nucleic acid phage display library having seven variegatedresidues (residues number 78-84) in the FG loop and five variegatedresidues (residue number 26-30) in the BC loop was prepared.Variegations in the BC loop were prepared by site-directed mutagenesis(Kunkel, et al.) using the BC3 oligonucleotide described in Table 1.Variegations in the FG loop were introduced using site-directedmutagenesis using the BC loop library as the starting material, therebyresulting in libraries containing variegations in both BC and FG loops.The oligonucleotide FG2 has variegating residues 78-84 andoligonucleotide FG4 has variegating residues 77-81 and a deletion ofresidues 82-84.

[0167] A nucleic acid phage display library having five variegatedresidues (residues 78-84) in the FG loop and a three residue deletion(residues 82-84) in the FG loop, and five variegated residues (residues26-30) in the BC loop, was prepared. The shorter FG loop was made in anattempt to reduce the flexibility of the FG loop; the loop was shown tobe highly flexible in Fn3 by the NMR studies of Main, et al. (1992). Ahighly flexible loop may be disadvantageous to forming a binding sitewith a high affinity (a large entropy loss is expected upon the ligandbinding, because the flexible loop should become more rigid). Inaddition, other Fn3 domains (besides human) have shorter FG loops (forsequence alignment, see FIG. 12 in Dickinson, et al. (1994)).

[0168] Randomization was achieved by the use of oligonucleotidescontaining degenerate nucleotide sequence (oligonucleotide BC3 forvariegating the BC loop and oligonucleotides FG2 and FG4 for variegatingthe FG loops).

[0169] Site-directed mutagenesis was performed following publishedmethods (see for example, Kunkel, 1985). The libraries were constructedby electrotransforming E. coli XL-1 Blue (Stratagene). Typically alibrary contains 10⁸ to 10⁹ independent clones. Library 2 contains fivevariegated residues in the BC loop and seven variegated residues in theFG loop. Library 4 contains five variegated residues in each of the BCand FG loops, and the length of the FG loop was shortened by threeresidues.

EXAMPLE VII fd Phage Display Libraries Constructed with LoopVariegations

[0170] Phage display libraries are constructed using the fd phage as thegenetic vector. The Fn3 gene is inserted in fUSE5 (Parmley & Smith,1988) using SflI restriction sites which are introduced at the 5′ and 3′ends of the Fn3 gene using PCR. The expression of this phage results inthe display of the fusion pIII protein on the surface of the fd phage.Variegations in the Fn3 loops are introduced using site-directedmutagenesis as described hereinabove, or by subcloning the Fn3 librariesconstructed in M13 phage into the fUSE5 vector.

EXAMPLE VIII Other Phage Display Libraries

[0171] T7 phage libraries (Novagen, Madison, Wis.) and bacterial piliexpression systems (Invitrogen) are also useful to express the Fn3 gene.

EXAMPLE IX Isolation of Polypeptides which Bind to MacromolecularStructures

[0172] The selection of phage-displayed monobodies was performedfollowing the protocols of Barbas and coworkers (Rosenblum & Barbas,1995). Briefly, approximately 1 μg of a target molecule (“antigen”) insodium carbonate buffer (100 mM, pH 8.5) was immobilized in the wells ofa microtiter plate (Maxisorp, Nunc) by incubating overnight at 4° C. inan air tight container. After the removal of this solution, the wellswere then blocked with a 3% solution of BSA (Sigma, Fraction V) in TBSby incubating the plate at 37° C. for 1 hour. A phagemid librarysolution (50 μl) containing approximately 10¹² colony forming units(cfu) of phagemid was absorbed in each well at 37° C. for 1 hour. Thewells were then washed with an appropriate buffer (typically TBST, 50 mMTris-HCl (pH 7.5), 150 mM NaCl, and 0.5% Tween20) three times (once forthe first round). Bound phage were eluted by an acidic solution(typically, 0.1 M glycine-HCl, pH 2.2; 50 μl) and recovered phage wereimmediately neutralized with 3 μl of Tris solution. Alternatively, boundphage were eluted by incubating the wells with 50 μl of TBS containingthe antigen (1-10 μM). Recovered phage were amplified using the standardprotocol employing the XL1Blue cells as the host (Sambrook, et al). Theselection process was repeated 5-6 times to concentrate positive clones.After the final round, individual clones were picked and their bindingaffinities and DNA sequences were determined.

[0173] The binding affinities of monobodies on the phage surface werecharacterized using the phage ELISA technique (Li, et al., 1995). Wellsof microtiter plates (Nunc) were coated with an antigen and blocked withBSA. Purified phages (10⁸-10¹¹ cfu) originating from a single colonywere added to each well and incubated 2 hours at 37° C. After washingwells with an appropriate buffer (see above), bound phage were detectedby the standard ELISA protocol using antiM13 antibody (rabbit, Sigma)and anti-rabbit Ig-peroxidase conjugate (Pierce). Colorimetric assayswere performed using Turbo-TMB (3,3′,5,5′-tetramethylbenzidine, Pierce)as a substrate.

[0174] The binding affinities of monobodies on the phage surface werefurther characterized using the competition ELISA method(Djavadi-Ohaniance, et al., 1996). In this experiment, phage ELISA isperformed in the same manner as described above, except that the phagesolution contains a ligand at varied concentrations. The phage solutionwas incubated a 4° C. for one hour prior to the binding of animmobilized ligand in a microtiter plate well. The affinities of phagedisplayed monobodies are estimated by the decrease in ELISA signal asthe free ligand concentration is increased.

[0175] After preliminary characterization of monobodies displayed on thesurface of phage using phage ELISA, genes for positive clones weresubcloned into the expression vector pAS45. E. coli BL21 (DE3) (Novagen)was transformed with an expression vector (pAS45 and its derivatives).Cells were grown in M9 minimal medium and M9 medium supplemented withBactotryptone (Difco) containing ampicillin (200 μg/ml). For isotopiclabeling, ¹⁵N NH⁴Cl and/or ¹³C glucose replaced unlabeled components.Stable isotopes were purchased from Isotec and Cambridge Isotope Labs.500 ml medium in a 2 l baffle flask was inoculated with 10 ml ofovernight culture and agitated at approximately 140 rpm at 37° C. IPTGwas added at a final concentration of 1 mM to induce protein expressionwhen OD(600 nm) reached approximately 1.0. The cells were harvested bycentrifugation 3 hours after the addition of IPTG and kept frozen at−70° C. until used.

[0176] Fn3 and monobodies with His•tag were purified as follows. Cellswere suspended in 5 ml/(g cell) of 50 mM Tris (pH 7.6) containing 1 mMphenylmethylsulfonyl fluoride. HEL (Sigma, 3×crystallized) was added toa final concentration of 0.5 mg/ml. After incubating the solution for 30min at 37° C., it was sonicated so as to cause cell breakage three timesfor 30 seconds on ice. Cell debris was removed by centrifugation at15,000 rpm in an Sorval RC-2B centrifuge using an SS-34 rotor.Concentrated sodium chloride is added to the solution to a finalconcentration of 0.5 M. The solution was then applied to a 1 ml HISTRAP™chelating column (Pharmacia) preloaded with nickel chloride (0.1 M, 1ml) and equilibrated in the Tris buffer (50 mM, pH 8.0) containing 0.5 Msodium chloride. After washing the column with the buffer, the boundprotein was eluted with a Tris buffer (50 mM, pH 8.0) containing 0.5 Mimidazole. The His•tag portion was cleaved off, when required, bytreating the fusion protein with thrombin using the protocol supplied byNovagen (Madison, Wis.). Fn3 was separated from the His•tag peptide andthrombin by a RESOURCES® column (Pharmacia) using a linear gradient ofsodium chloride (0-0.5 M) in sodium acetate buffer (20 mM, pH 5.0).

[0177] Small amounts of soluble monobodies were prepared as follows.XL-1 Blue cells containing pAS38 derivatives (plasmids coding Fn3-pIIIfusion proteins) were grown in LB media at 37° C. with vigorous shakinguntil OD (600 nm) reached approximately 1.0; IPTG was added to theculture to a final concentration of 1 mM, and the cells were furthergrown overnight at 37° C. Cells were removed from the medium bycentrifugation, and the supernatant was applied to a microtiter wellcoated with a ligand. Although XL-1 Blue cells containing pAS38 and itsderivatives express FN3-pIII fusion proteins, soluble proteins are alsoproduced due to the cleavage of the linker between the Fn3 and pIIIregions by proteolytic activities of E. coli (Rosenblum & Barbas, 1995).Binding of a monobody to the ligand was examined by the standard ELISAprotocol using a custom antibody against Fn3 (purchased from CocalicoBiologicals, Reamstown, Pa.). Soluble monobodies obtained from theperiplasmic fraction of E. coli cells using a standard osmotic shockmethod were also used.

EXAMPLE X Ubiquitin Binding Monobody

[0178] Ubiquitin is a small (76 residue) protein involved in thedegradation pathway in eurkaryotes. It is a single domain globularprotein. Yeast ubiquitin was purchased from Sigma Chemical Company andwas used without further purification.

[0179] Libraries 2 and 4, described in Example VI above, were used toselect ubiquitin-binding monobodies. Ubiquitin (1 μg in 50 μl sodiumbicarbonate buffer (100 mM, pH 8.5)) was immobilized in the wells of amicrotiter plate, followed by blocking with BSA (3% in TBS). Panning wasperformed as described above. In the first two rounds, 1 μg of ubiquitinwas immobilized per well, and bound phage were elute with an acidicsolution. From the third to the sixth rounds, 0.1 μg of ubiquitin wasimmobilized per well and the phage were eluted either with an acidicsolution or with TBS containing 10 μM ubiquitin.

[0180] Binding of selected clones was tested first in the polyclonalmode, i.e., before isolating individual clones. Selected clones from alllibraries showed significant binding to ubiquitin. These results areshown in FIG. 9. The binding to the immobilized ubiquitin of the cloneswas inhibited almost completely by less than 30 μm soluble ubiquitin inthe competition ELISA experiments (see FIG. 10). The sequences of the BCand FG loops of ubiquitin-binding monobodies is shown in Table 3. TABLE3 Sequences of ubiquitin-binding monobodies Oc- curr- ence (if more thanName BC loop FG loop one) 211 CARRA (SEQ ID NO:31) RWIPLAK (SEQ IDNO:32) 2 212 CWRRA (SEQ ID NO:33) RWVGLAW (SEQ ID NO:34) 213 CKHRR (SEQID NO:35) FADLWWR (SEQ ID NO:36) 214 CRRGR (SEQ ID NO:37) RGFMWLS (SEQID NO:38) 215 CNWRR (SEQ ID NO:39) RAYRYRW (SEQ ID NO:40) 411 SRLRR (SEQID NO:41) PPWRV (SEQ ID NO:42) 9 422 ARWTL (SEQ ID NO:43) RRWWW (SEQ IDNO:44) 424 GQRTF (SEQ ID NO:45) RRWWA (SEQ ID NO:46)

[0181] The 411 clone, which was the most enriched clone, wascharacterized using phage ELISA. The 411 clone showed selective bindingand inhibition of binding in the presence of about 10 μM ubiquitin insolution (FIG. 11).

EXAMPLE XI Methods for the Immobilization of Small Molecules

[0182] Target molecules were immobilized in wells of a microtiter plate(MAXISORP, Nunc) as described hereinbelow, and the wells were blockedwith BSA. In addition to the use of carrier protein as described below,a conjugate of a target molecule in biotin can be made. The biotinylatedligand can then be immobilized to a microtiter plate well which has beencoated with streptavidin.

[0183] In addition to the use of a carrier protein as described below,one could make a conjugate of a target molecule and biotin (Pierce) andimmobilize a biotinylated ligand to a microtiter plate well which hasbeen coated with streptavidin (Smith and Scott, 1993).

[0184] Small molecules may be conjugated with a carrier protein such asbovine serum albumin (BSA, Sigma), and passively adsorbed to themicrotiter plate well. Alternatively, methods of chemical conjugationcan also be used. In addition, solid supports other than microtiterplates can readily be employed.

EXAMPLE XII Fluorescein Binding Monobody

[0185] Fluorescein has been used as a target for the selection ofantibodies from combinatorial libraries (Barbas, et al. 1992).NHS-fluorescein was obtained from Pierce and used according to themanufacturer's instructions in preparing conjugates with BSA (Sigma).Two types of fluorescein-BSA conjugates were prepared with approximatemolar ratios of 17 (fluorescein) to one (BSA).

[0186] The selection process was repeated 5-6 times to concentratepositive clones. In this experiment, the phage library was incubatedwith a protein mixture (BSA, cytochrome C (Sigma, Horse) and RNaseA(Sigma, Bovine), 1 mg/ml each) at room temperature for 30 minutes, priorto the addition to ligand coated wells. Bound phage were eluted in TBScontaining 10 μM soluble fluorescein, instead of acid elution. After thefinal round, individual clones were picked and their binding affinities(see below) and DNA sequences were determined. TABLE 4 BC EG Clones fromLibrary #2 WT AVTVR (SEQ ID NO:47) RGDSPAS (SEQ ID NO:48) pLB24.1 CNWRR(SEQ ID NO:49) RAYRYRW (SEQ ID NO:50) pLB24.2 CMWRA (SEQ ID NO:51)RWGMLRR (SEQ ID NO:52) pLB24.3 ARMRE (SEQ ID NO:53) RWLRGRY (SEQ IDNO:54) pLB24.4 CARRR (SEQ ID NO:55) RRAGWGW (SEQ ID NO:56) pLB24.5 CNWRR(SEQ ID NO:57) RAYRYRW (SEQ ID NO:58) pLB24.6 RWRER (SEQ ID NO:59)RHPWTER (SEQ ID NO:60) pLB24.7 CNWRR (SEQ ID NO:61) RAYRYRW (SEQ IDNO:62) pLB24.8 ERRVP (SEQ ID NO:63) RLLLWQR (SEQ lID NO:64) pLB24.9GRGAG (SEQ ID NO:65) FGSFERR (SEQ ID NO:66) pLB24.11 CRWTR (SEQ IDNO:67) RRWFDGA (SEQ ID NO:68) pLB 24.12 CNWRR (SEQ ID NO:69) RAYRYRW(SEQ ID NO:70) Clones from Library #4 WT AVTVR (SEQ ID NO:71) GRGDS (SEQID NO:72) pLB25.1 GQRTF (SEQ ID NO:73) RRWWA (SEQ ID NO:74) pLB25.2GQRTF (SEQ ID NO:75) RRWWA (SEQ ID NO:76) pLB25.3 GQRTF (SEQ ID NO:77)RRWWA (SEQ ID NO:78) pLB25.4 LRYRS (SEQ ID NO:79) GWRWR (SEQ ID NO:80)pLB25.5 GQRTF (SEQ ID NO:81) RRWWA (SEQ ID NO:82) pLB25.6 GQRTF (SEQ IDNO:83) RRWWA (SEQ ID NO:84) pLB25.7 LRYRS (SEQ ID NO:85) GWRWR (SEQ IDNO:86) pLB25.9 LRYRS (SEQ ID NO:87) GWRWR (SEQ ID NO:88) pLB25.11 GQRTF(SEQ ID NO:89) RRWWA (SEQ ID NO:90) pLB25.12 LRYRS (SEQ ID NO:91) GWRWR(SEQ ID NO:92)

[0187] Preliminary characterization of the binding affinities ofselected clones were performed using phage ELISA and competition phageELISA (see FIG. 12 (Fluorescein-1) and FIG. 13 (Fluorescein-2)). Thefour clones tested showed specific binding to the ligand-coated wells,and the binding reactions are inhibited by soluble fluorescein (see FIG.13).

EXAMPLE XIII Digoxigenin Binding Monobody

[0188] Digoxigenin-3-O-methyl-carbonyl-e-aminocapronic acid-NHS(Boehringer Mannheim) is used to prepare a digoxigenin-BSA conjugate.The coupling reaction is performed following the manufacturers'instructions. The digoxigenin-BSA conjugate is immobilized in the wellsof a microtiter plate and used for panning. Panning is repeated 5 to 6times to enrich binding clones. Because digoxigenin is sparingly solublein aqueous solution, bound phages are eluted from the well using acidicsolution. See Example XIV.

EXAMPLE XIV TSAC (Transition State Analog Compound) Binding Monobodies

[0189] Carbonate hydrolyzing monobodies are selected as follows. Atransition state analog for carbonate hydrolysis, 4-nitrophenylphosphonate is synthesized by an Arbuzov reaction as describedpreviously (Jacobs and Schultz, 1987). The phosphonate is then coupledto the carrier protein, BSA, using carbodiimide, followed by exhaustivedialysis (Jacobs and Schultz, 1987). The hapten-BSA conjugate isimmobilized in the wells of a microtiter plate and monobody selection isperformed as described above. Catalytic activities of selectedmonobodies are tested using 4-nitrophenyl carbonate as the substrate.

[0190] Other haptens useful to produce catalytic monobodies aresummarized in H. Suzuki (1994) and in N. R. Thomas (1994).

EXAMPLE XV NMR Characterization of Fn3 and Comparison of the Fn3Secreted by Yeast with that Secreted by E. coli

[0191] Nuclear magnetic resonance (NMR) experiments are performed toidentify the contact surface between FnAb and a target molecule, e.g.,monobodies to fluorescein, ubiquitin, RNaseA and soluble derivatives ofdigoxigenin. The information is then be used to improve the affinity andspecificity of the monobody. Purified monobody samples are dissolved inan appropriate buffer for NMR spectroscopy using Amicon ultrafiltrationcell with a YM-3 membrane. Buffers are made with 90% H₂O/10% D₂O(distilled grade, Isotec) or with 100% D₂O. Deuterated compounds (e.g.acetate) are used to eliminate strong signals from them.

[0192] NMR experiments are performed on a Varian Unity INOVA 600spectrometer equipped with four RF channels and a triple resonance probewith pulsed field gradient capability. NMR spectra are analyzed usingprocessing programs such as FELIX (Molecular Simulations), NMRPIPE,PIPP, and CAPP (Garrett, et al., 1991; Delaglio, et al., 1995) on UNIXworkstations. Sequence specific resonance assignments are made usingwell-established strategy using a set of triple resonance experiments(CBCA(CO)NH and HNCACB) (Grzesiek & Bax, 1992; Wittenkind & Mueller,1993).

[0193] Nuclear Overhauser effect (NOE) is observed between ¹H nucleicloser than approximately 5 Å, which allows one to obtain information oninterproton distances. A series of double- and triple-resonanceexperiments (Table 5; for recent reviews on these techniques, see Bax &Grzesiek, 1993 and Kay, 1995) are performed to collect distance (i.e.NOE) and dihedral angle (J-coupling) constraints. Isotope-filteredexperiments are performed to determine resonance assignments of thebound ligand and to obtain distance constraints within the ligand andthose between FnAb and the ligand. Details of sequence specificresonance assignments and NOE peak assignments have been described indetail elsewhere (Clore & Gronenborn, 1991; Pascal, et al., 1994b;Metzler, et al., 1996). TABLE 5 NMR experiments for structurecharacterization Experiment Name Reference 1. reference spectra 2D-¹H,¹⁵N-HSQC (Bodenhausen & Ruben, 1980; Kay, et al., 1992) 2D-¹H, ¹³C-HSQC(Bodenhausen & Ruben, 1980; Vuister & Bax, 1992) 2. backbone and sidechain resonance assignments of ¹³C/¹⁵N-labeled protein 3D-CBCA(CO)NH(Grzesiek & Bax, 1992) 3D-HNCACB (Wittenkind & Mueller, 1993) 3D-C(CO)NH(Logan et al., 1992; Grzesiek et al., 1993) 3D-H(CCO)NH3D-HBHA(CBCACO)NH (Grzesiek & Bax, 1993) 3D-HCCH-TOCSY (Kay et al.,1993) 3D-HCCH-COSY (Ikura et al., 1991) 3D-¹H, ¹⁵N-TOCSY-HSQC (Zhang etal., 1994) 2D-HB(CBCDCE)HE (Yamazaki et al., 1993) 3. resonanceassignments of unlabeled ligand 2D-isotope-filtered ¹H-TOCSY2D-isotope-filtered ¹H-COSY 2D-isotope-filtered ¹H-NOESY (Ikura & Bax,1992) 4. structural constraints within labeled protein 3D-¹H,¹⁵N-NOESY-HSQC (Zhang et al., 1994) 4D-¹H, ¹³C-HMQC-NOESY-HMQC (Vuisteret al., 1993) 4D-¹H, ¹³C, ¹⁵N-HSQC-NOESY-HSQC (Muhandiram et al., 1993;Pascal et al., 1994a) within unlabeled ligand 2D-isotope-filtered¹H-NOESY (Ikura & Bax, 1992) interactions between protein and ligand3D-isotope-filtered ¹H, ¹⁵N-NOESY-HSQC 3D-isotope-filtered ¹H,¹³C-NOESY-HSQC (Lee et al., 1994) 5. dihedral angle constraintsJ-molulated ¹H, ¹⁵N-HSQC (Billeter et al., 1992) 3D-HNHB (Archer et al.,1991)

[0194] Backbone ¹H, ¹⁵N and ¹³C resonance assignments for a monobody arecompared to those for wild-type Fn3 to assess structural changes in themutant. Once these data establish that the mutant retains the globalstructure, structural refinement is performed using experimental NOEdata. Because the structural difference of a monobody is expected to beminor, the wild-type structure can be used as the initial model aftermodifying the amino acid sequence. The mutations are introduced to thewild-type structure by interactive molecular modeling, and then thestructure is energy-minimized using a molecular modeling program such asQUANTA (Molecular Simulations). Solution structure is refined usingcycles of dynamical simulated annealing (Nilges et al., 1988) in theprogram X-PLOR (Brünger, 1992). Typically, an ensemble of fiftystructures is calculated. The validity of the refined structures isconfirmed by calculating a fewer number of structures from randomlygenerated initial structures in X-PLOR using the YASAP protocol (Nilges,et al., 1991). Structure of a monobody-ligand complex is calculated byfirst refining both components individually using intramolecular NOEs,and then docking the two using intermolecular NOEs.

[0195] For example, the ¹H, ¹⁵N-HSQC spectrum for thefluorescein-binding monobody LB25.5 is shown in FIG. 14. The spectrumshows a good dispersion (peaks are spread out) indicating that LB25.5 isfolded into a globular conformation. Further, the spectrum resemblesthat for the wild-type Fn3, showing that the overall structure of LB25.5is similar to that of Fn3. These results demonstrate that ligand-bindingmonobodies can be obtained without changing the global fold of the Fn3scaffold.

[0196] Chemical shift perturbation experiments are performed by formingthe complex between an isotope-labeled FnAb and an unlabeled ligand. Theformation of a stoichiometric complex is followed by recording the HSQCspectrum. Because chemical shift is extremely sensitive to nuclearenvironment, formation of a complex usually results in substantialchemical shift changes for resonances of amino acid residues in theinterface. Isotope-edited NMR experiments (2D HSQC and 3D CBCA(CO)NH)are used to identify the resonances that are perturbed in the labeledcomponent of the complex; i.e. the monobody. Although the possibility ofartifacts due to long-range conformational changes must always beconsidered, substantial differences for residues clustered on continuoussurfaces are most likely to arise from direct contacts (Chen et al,1993; Gronenborn & Clore, 1993).

[0197] An alternative method for mapping the interaction surfaceutilizes amide hydrogen exchange (HX) measurements. HX rates for eachamide proton are measured for ¹⁵N labeled monobody both free andcomplexed with a ligand. Ligand binding is expected to result indecreased amide HX rates for monobody residues in the interface betweenthe two proteins, thus identifying the binding surface. HX rates formonobodies in the complex are measured by allowing HX to occur for avariable time following transfer of the complex to D₂O; the complex isdissociated by lowering pH and the HSQC spectrum is recorded at low pHwhere amide HX is slow. Fn3 is stable and soluble at low pH, satisfyingthe prerequisite for the experiments.

EXAMPLE XVI Construction and Analysis of Fn3-Display System Specific forUbiquitin

[0198] An Fn3-display system was designed and synthesized,ubiquitin-binding clones were isolated and a major Fn3 mutant in theseclones was biophysically characterized.

[0199] Gene construction and phage display of Fn3 was performed as inExamples I and II above. The Fn3-phage pIII fusion protein was expressedfrom a phagemid-display vector, while the other components of the M13phage, including the wildtype pIII, were produced using a helper phage(Bass et al., 1990). Thus, a phage produced by this system shouldcontain less than one copy of Fn3 displayed on the surface. The surfacedisplay of Fn3 on the phage was detected by ELISA using an anti-Fn3antibody. Only phages containing the Fn3-pIII fusion vector reacted withthe antibody.

[0200] After confirming the phage surface to display Fn3, a phagedisplay library of Fn3 was constructed as in Example III. Randomsequences were introduced in the BC and FG loops. In the first library,five residues (77-81) were randomized and three residues (82-84) weredeleted from the FG loop. The deletion was intended to reduce theflexibility and improve the binding affinity of the FG loop. Fiveresidues (26-30) were also randomized in the BC loop in order to providea larger contact surface with the target molecule. Thus, the resultinglibrary contains five randomized residues in each of the BC and FG loops(Table 6). This library contained approximately 10⁸ independent clones.

[0201] Library Screening

[0202] Library screening was performed using ubiquitin as the targetmolecule. In each round of panning, Fn3-phages were absorbed to aubiquitin-coated surface, and bound phages were eluted competitivelywith soluble ubiquitin. The recovery ratio improved from 4.3×10⁻⁷ in thesecond round to 4.5×10⁻⁶ in the fifth round, suggesting an enrichment ofbinding clones. After five founds of panning, the amino acid sequencesof individual clones were determined (Table 6). TABLE 6 Sequences in thevariegated loops of enriched clones Name BC loop FG loop Frequency WildType GCAGTTACCGTGCGT GGCCGTGGTGACAGCCCAGCGAGC — (SEQ ID NO:93) (SEQ IDNO:95) AlaValThrValArg GlyArgGlyAspSerProAlaSer (SEQ ID NO:94) (SEQ IDNO:96) Library^(a) NNKNNKNNKNNKNNK NNKNNKNNKNNKNNK--------- — XXXXXXXXXX(deletion) clone1 TCGAGGTTGCGGCGG CCGCCGTGGAGGGTG 9 (SEQ ID NO:97)(SEQ ID NO:99) (Ubi4) SerArgLeuArgArg ProProTrpArgVal (SEQ ID NO:98)(SEQ ID NO:100) clone2 GGTCAGCGAACTTTT AGGCGGTGGTGGGCT 1 (SEQ ID NO:101)(SEQ ID NO:103) GlyGlnArgThrPhe ArgArgTrpTrpAla (SEQ ID NO:102) (SEQ IDNO:104) clone3 GCGAGGTGGACGCTT AGGCGGTGGTGGTGG 1 (SEQ ID NO:105) (SEQ IDNO:107) AlaArgTrpThrLeu ArgArgTrpTrpTrp (SEQ ID NO:106) (SEQ ID NO:108)

[0203] A clone, dubbed Ubi4, dominated the enriched pool of Fn3variants. Therefore, further investigation was focused on this Ubi4clone. Ubi4 contains four mutations in the BC loop (Arg 30 in the BCloop was conserved) and five mutations and three deletions in the FGloop. Thus 13% (12 out of 94) of the residues were altered in Ubi4 fromthe wild-type sequence.

[0204]FIG. 15 shows a phage ELISA analysis of Ubi4. The Ubi4 phage bindsto the target molecule, ubiquitin, with a significant affinity, while aphage displaying the wild-type Fn3 domain or a phase with no displayedmolecules show little detectable binding to ubiquitin (FIG. 15a). Inaddition, the Ubi4 phage showed a somewhat elevated level of backgroundbinding to the control surface lacking the ubiquitin coating. Acompetition ELISA experiments shows the IC₅₀ (concentration of the freeligand which causes 50% inhibition of binding) of the binding reactionis approximately 5 μM (FIG. 15b). BSA, bovine ribonuclease A andcytochrome C show little inhibition of the Ubi4-ubiquitin bindingreaction (FIG. 15c), indicating that the binding reaction of Ubi4 toubiquitin does result from specific binding.

Characterization of a Mutant Fn3 Protein

[0205] The expression system yielded 50-100 mg Fn3 protein per literculture. A similar level of protein expression was observed for the Ubi4clone and other mutant Fn3 proteins.

[0206] Ubi4-Fn3 was expressed as an independent protein. Though amajority of Ubi4 was expressed in E. coli as a soluble protein, itssolubility was found to be significantly reduced as compared to that ofwild-type Fn3. Ubi4 was soluble up to ˜20 μM at low pH, with much lowersolubility at neutral pH. This solubility was not high enough fordetailed structural characterization using NMR spectroscopy or X-raycrystallography.

[0207] The solubility of the Ubi4 protein was improved by adding asolubility tail, GKKGK, as a C-terminal extension. The gene for Ubi4-Fn3was subcloned into the expression vector pAS45 using PCR. The C-terminalsolubilization tag, GKKGK, was incorporated in this step. E. coli BL21(DE3) (Novagen) was transformed with the expression vector (pAS45 andits derivatives). Cells were grown in M9 minimal media and M9 mediasupplemented with Bactotryptone (Difco) containing ampicillin (200μg/ml). For isotopic labeling, ¹⁵N NH₄Cl replaced unlabeled NH₄Cl in themedia. 500 ml medium in a 2 liter baffle flask was inoculated with 10 mlof overnight culture and agitated at 37° C. IPTG was added at a finalconcentration of 1 mM to initiate protein expression when OD (600 nm)reaches one. The cells were harvested by centrifugation 3 hours afterthe addition of IPTG and kept frozen at 70° C. until used.

[0208] Proteins were purified as follows. Cells were suspended in 5ml/(g cell) of Tris (50 mM, pH 7.6) containing phenylmethylsulfonylfluoride (1 mM). Hen egg lysozyme (Sigma) was added to a finalconcentration of 0.5 mg/ml. After incubating the solution for 30 minutesat 37° C., it was sonicated three times for 30 seconds on ice. Celldebris was removed by centrifugation. Concentrated sodium chloride wasadded to the solution to a final concentration of 0.5 M. The solutionwas applied to a HI-TRAP chelating column (Pharmacia) preloaded withnickel and equilibrated in the Tris buffer containing sodium chloride(0.5 M). After washing the column with the buffer, histag-Fn3 was elutedwith the buffer containing 500 mM imidazole. The protein was furtherpurified using a RESOURCES® column (Pharmacia) with a NaCl gradient in asodium acetate buffer (20 mM, pH 4.6).

[0209] With the GKKGK (SEQ ID NO:109) tail, the solubility of the Ubi4protein was increased to over 1 mM at low pH and up to ˜50 μM at neutralpH. Therefore, further analyses were performed on Ubi4 with thisC-terminal extension (hereafter referred to as Ubi4-K). It has beenreported that the solubility of a minibody could be significantlyimproved by addition of three Lys residues at the N- or C-termini(Bianchi et al., 1994). In the case of protein Rop, a non-structuredC-terminal tail is critical in maintaining its solubility (Smith et al.,1995).

[0210] Oligomerization states of the Ubi4 protein were determined usinga size exclusion column. The wild-type Fn3 protein was monomeric at lowand neutral pH's. However, the peak of the Ubi4-K protein wassignificantly broader than that of wild-type Fn3, and eluted after thewild-type protein. This suggests interactions between Ubi4-K and thecolumn material, precluding the use of size exclusion chromatography todetermine the oligomerization state of Ubi4. NMR studies suggest thatthe protein is monomeric at low pH.

[0211] The Ubi4-K protein retained a binding affinity to ubiquitin asjudged by ELISA (FIG. 15d). However, an attempt to determine thedissociation constant using a biosensor (Affinity Sensors, Cambridge,U.K.) failed because of high background binding of Ubi4-K-Fn3 to thesensor matrix. This matrix mainly consists of dextran, consistent withour observation that interactions between Ubi4-K interacts with thecross-linked dextran of the size exclusion column.

EXAMPLE XVII Stability Measurements of Monobodies

[0212] Guanidine hydrochloride (GuHCl)-induced unfolding and refoldingreactions were followed by measuring tryptophan fluorescence.Experiments were performed on a Spectronic AB-2 spectrofluorometerequipped with a motor-driven syringe (Hamilton Co.). The cuvettetemperature was kept at 30° C. The spectrofluorometer and the syringewere controlled by a single computer using a home-built interface. Thissystem automatically records a series of spectra following GuHCltitration. An experiment started with a 1.5 ml buffer solutioncontaining 5 μM protein. An emission spectrum (300-400 nm; excitation at290 nm) was recorded following a delay (3-5 minutes) after eachinjection (50 or 100 μl) of a buffer solution containing GuHCl. Thesesteps were repeated until the solution volume reached the full capacityof a cuvette (3.0 ml). Fluorescence intensities were normalized asratios to the intensity at an isofluorescent point which was determinedin separate experiments. Unfolding curves were fitted with a two-statemodel using a nonlinear least-squares routine (Santoro & Bolen, 1988).No significant differences were observed between experiments with delaytimes (between an injection and the start of spectrum acquisition) of 2minutes and 10 minutes, indicating that the unfolding/refoldingreactions reached close to an equilibrium at each concentration pointwithin the delay times used.

[0213] Conformational stability of Ubi4-K was measured usingabove-described GuHCl-induced unfolding method. The measurements wereperformed under two sets of conditions; first at pH 3.3 in the presenceof 300 mM sodium chloride, where Ubi4-K is highly soluble, and second inTBS, which was used for library screening. Under both conditions, theunfolding reaction was reversible, and we detected no signs ofaggregation or irreversible unfolding. FIG. 16 shows unfoldingtransitions of Ubi4-K and wild-type Fn3 with the N-terminal (his)₆ tagand the C-terminal solubility tag. The stability of wild-type Fn3 wasnot significantly affected by the addition of these tags. Parameterscharacterizing the unfolding transitions are listed in Table 7. TABLE 7Stability parameters for Ubi4 and wild-type Fn3 as determined by GuHCl-induced unfolding Protein ΔG₀ (kcal mol⁻¹) m_(G) (kcal mol⁻¹ M⁻¹) Ubi4(pH 7.5) 4.8 ± 0.1 2.12 ± 0.04 Ubi4 (pH 3.3) 6.5 ± 0.1 2.07 ± 0.02Wild-type (pH 7.5) 7.2 ± 0.2 1.60 ± 0.04 Wild-type (pH 3.3) 11.2 ± 0.1 2.03 ± 0.02

[0214] ΔG₀ is the free energy of unfolding in the absence of denaturant;m_(G) is the dependence of the free energy of unfolding on GuHClconcentration. For solution conditions, see FIG. 4 caption.

[0215] Though the introduced mutations in the two loops certainlydecreased the stability of Ubi4-K relative to wild-type Fn3, thestability of Ubi4 remains comparable to that of a “typical” globularprotein. It should also be noted that the stabilities of the wild-typeand Ubi4-K proteins were higher at pH 3.3 than at pH 7.5.

[0216] The Ubi4 protein had a significantly reduced solubility ascompared to that of wild-type Fn3, but the solubility was improved bythe addition of a solubility tail. Since the two mutated loops comprisethe only differences between the wild-type and Ubi4 proteins, theseloops must be the origin of the reduced solubility. At this point, it isnot clear whether the aggregation of Ubi4-K is caused by interactionsbetween the loops, or by interactions between the loops and theinvariable regions of the Fn3 scaffold.

[0217] The Ubi4-K protein retained the global fold of Fn3, showing thatthis scaffold can accommodate a large number of mutations in the twoloops tested. Though the stability of the Ubi4-K protein issignificantly lower than that of the wild-type Fn3 protein, the Ubi4protein still has a conformational stability comparable to those forsmall globular proteins. The use of a highly stable domain as a scaffoldis clearly advantageous for introducing mutations without affecting theglobal fold of the scaffold. In addition, the GuHCl-induced unfolding ofthe Ubi4 protein is almost completely reversible. This allows thepreparation of a correctly folded protein even when a Fn3 mutant isexpressed in a misfolded form, as in inclusion bodies. The modeststability of Ubi4 in the conditions used for library screening indicatesthat Fn3 variants are folded on the phage surface. This suggests that aFn3 clone is selected by its binding affinity in the folded form, not ina denatured form. Dickinson et al. proposed that Val 29 and Arg 30 inthe BC loop stabilize Fn3. Val 29 makes contact with the hydrophobiccore, and Arg 30 forms hydrogen bonds with Gly 52 and Val 75. InUbi4-Fn3, Val 29 is replaced with Arg, while Arg 30 is conserved. The FGloop was also mutated in the library. This loop is flexible in thewild-type structure, and shows a large variation in length among humanFn3 domains (Main et al., 1992). These observations suggest thatmutations in the FG loop may have less impact on stability. In addition,the N-terminal tail of Fn3 is adjacent to the molecular surface formedby the BC and FG loops (FIGS. 1 and 17) and does not form a well-definedstructure. Mutations in the N-terminal tail would not be expected tohave strong detrimental effects on stability. Thus, residues in theN-terminal tail may be good sites for introducing additional mutations.

EXAMPLE XVIII NMR Spectroscopy of Ubi4-Fn3

[0218] Ubi4-Fn3 was dissolved in [²H]-Gly HCl buffer (20 mM, pH 3.3)containing NaCl (300 mM) using an Amicon ultrafiltration unit. The finalprotein concentration was 1 mM. NMR experiments were performed on aVarian Unity INOVA 600 spectrometer equipped with a triple-resonanceprobe with pulsed field gradient. The probe temperature was set at 30°C. HSQC, TOCSY-HSQC and NOESY-HSQC spectra were recorded using publishedprocedures (Kay et al., 1992; Zhang et al., 1994). NMR spectra wereprocessed and analyzed using the NMRPIPE and NMRVIEW software (Johnson &Blevins, 1994; Delaglio et al., 1995) on UNIX workstations.Sequence-specific resonance assignments were made using standardprocedures (Wüthrich, 1986; Clore & Gronenborn, 1991). The assignmentsfor wild-type Fn3 (Baron et al., 1992) were confirmed using a¹⁵N-labeled protein dissolved in sodium acetate buffer (50 mM, pH 4.6)at 30° C.

[0219] The three-dimensional structure of Ubi4-K was characterized usingthis heteronuclear NMR spectroscopy method. A high quality spectrumcould be collected on a 1 mM solution of ¹⁵N-labeled Ubi4 (FIG. 17a) atlow pH. The linewidth of amide peaks of Ubi4-K was similar to that ofwild-type Fn3, suggesting that Ubi4-K is monomeric under the conditionsused. Complete assignments for backbone ¹H and ¹⁵N nuclei were achievedusing standard ¹H, ¹⁵N double resonance techniques, except for a row ofHis residues in the N-terminal (His)₆ tag. There were a few weak peaksin the HSQC spectrum which appeared to originate from a minor speciescontaining the N-terminal Met residue. Mass spectroscopy analysis showedthat a majority of Ubi4-K does not contain the N-terminal Met residue.FIG. 17 shows differences in ¹HN and ¹⁵N chemical shifts between Ubi4-Kand wild-type Fn3. Only small differences are observed in the chemicalshifts, except for those in and near the mutated BC and FG loops. Theseresults clearly indicate that Ubi4-K retains the global fold of Fn3,despite the extensive mutations in the two loops. A few residues in theN-terminal region, which is close to the two mutated loops, also exhibitsignificant chemical differences between the two proteins. An HSQCspectrum was also recorded on a 50 μM sample of Ubi4-K in TBS. Thespectrum was similar to that collected at low pH, indicating that theglobal conformation of Ubi4 is maintained between pH 7.5 and 3.3.

[0220] The complete disclosure of all patents, patent documents andpublications cited herein are incorporated by reference as ifindividually incorporated. The foregoing detailed description andexamples have been given for clarity of understanding only. Nounnecessary limitations are to be understood therefrom. The invention isnot limited to the exact details shown and described for variationsobvious to one skilled in the art will be included within the inventiondefined by the claims.

0 SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES:118 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 1: Ala Arg Glu Arg Asp Tyr Arg Leu AspTyr Trp Gly Gln Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 2: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: aminoacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:Ala Arg Gly Ala Val Val Ser Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 1 5 1015 Gly (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Tyr Ala Val Thr Gly Arg Gly AspSer Pro Ala Ser Ser Lys Pro Ile 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE:amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENTTYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ IDNO: 4: Tyr Ala Glu Arg Asp Tyr Arg Leu Asp Tyr Pro Ile 1 5 10 (2)INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 5: Tyr Ala Val Arg Asp Tyr Arg Leu AspTyr Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 16 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Tyr AlaVal Arg Asp Tyr Arg Leu Asp Tyr Ala Ser Ser Lys Pro Ile 1 5 10 15 (2)INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:13 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 7: Tyr Ala Val Arg Asp Tyr Arg Leu AspTyr Lys Pro Ile 1 5 10 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Tyr AlaVal Arg Asp Tyr Arg Ser Lys Pro Ile 1 5 10 (2) INFORMATION FOR SEQ IDNO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B)TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 9: Tyr Ala Val Thr Arg Asp Tyr Arg Leu Ser Ser Lys Pro Ile 15 10 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 15 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Tyr Ala Val Thr Glu Arg AspTyr Arg Leu Ser Ser Lys Pro Ile 1 5 10 15 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 amino acids (B) TYPE:amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENTTYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ IDNO: 11: Tyr Ala Val Ala Val Val Ser Tyr Tyr Ala Met Asp Tyr Pro Ile 1 510 15 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 16 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Tyr Ala Val Thr Ala Val ValSer Tyr Tyr Ala Ser Ser Lys Pro Ile 1 5 10 15 (2) INFORMATION FOR SEQ IDNO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 59 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 13: CGGGATCCCA TATGCAGGTT TCTGATGTTC CGCGTGACCT GGAAGTTGTTGCTGCGACC 59 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 55 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: TAACTGCAGGAGCATCCCAG CTGATCAGCA GGCTAGTCGG GGTCGCAGCA ACAAC 55 (2) INFORMATION FORSEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear(ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 15: CTCCTGCAGT TACCGTGCGT TATTACCGTA TCACGTACGG TGAAACCGGT G51 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GTGAATTCCT GAACCGGGGAGTTACCACCG GTTTCACCG 39 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 46 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: AGGAATTCACTGTACCTGGT TCCAAGTCTA CTGCTACCAT CAGCGG 46 (2) INFORMATION FOR SEQ IDNO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 18: GTATAGTCGA CACCCGGTTT CAGGCCGCTG ATGGTAGC 38 (2)INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:32 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 19: CGGGTGTCGA CTATACCATC ACTGTATACG CT32 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 55 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: CGGGATCCGA GCTCGCTGGGCTGTCACCAC GGCCAGTAAC AGCGTATACA GTGAT 55 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:CAGCGAGCTC CAAGCCAATC TCGATTAACT ACCGT 35 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:CGGGATCCTC GAGTTACTAG GTACGGTAGT TAATCGA 37 (2) INFORMATION FOR SEQ IDNO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 23: CGGGATCCAC GCGTGCCACC GGTACGGTAG TTAATCGA 38 (2)INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH:44 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 24: CGGGATCCAC GCGTCCATTC GTTTGTGAATATCAAGGCCA ATCG 44 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: CCGGAAGCTTTAAGACTCCT TATTACGCAG TATGTTAGC 39 (2) INFORMATION FOR SEQ ID NO: 26:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE:nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULETYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:CTGTTACTGG CCGTGAGATC TAACCAGCGA GCTCCA 36 (2) INFORMATION FOR SEQ IDNO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 27: GATCAGCTGG GATGCTCCTN NKNNKNNKNN KNNKTATTAC CGTATCACGT A51 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: TGTATACGCT GTTACTGGCNNKNNKNNKNN KNNKNNKNNK TCCAAGCCAA TCTCGAT 57 (2) INFORMATION FOR SEQ IDNO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 47 base pairs (B)TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 29: CTGTATACGC TGTTACTGGC NNKNNKNNKN NKCCAGCGAG CTCCAAG 47(2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: CATCACTGTA TACGCTGTTACTNNKNNKNN KNNKNNKTCC AAGCCAATCT C 51 (2) INFORMATION FOR SEQ ID NO: 31:(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: aminoacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:Cys Ala Arg Arg Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: Arg TrpIle Pro Leu Ala Lys 1 5 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: Cys TrpArg Arg Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: Arg TrpVal Gly Leu Ala Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: Cys LysHis Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: Phe AlaAsp Leu Trp Trp Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: Cys ArgArg Gly Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: Arg GlyPhe Met Trp Leu Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: Cys AsnTrp Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: Arg AlaTyr Arg Tyr Arg Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: Ser ArgLeu Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: Pro ProTrp Arg Val 1 5 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: Ala ArgTrp Thr Leu 1 5 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: Arg ArgTrp Trp Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: Gly GlnArg Thr Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: Ala ValThr Val Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: Arg GlyAsp Ser Pro Ala Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: Cys AsnTrp Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: Arg AlaTyr Arg Tyr Arg Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: Cys MetTrp Arg Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: Arg TrpGly Met Leu Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: Ala ArgMet Arg Glu 1 5 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: Arg TrpLeu Arg Gly Arg Tyr 1 5 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55: Cys AlaArg Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: Arg ArgAla Gly Trp Gly Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57: Cys AsnTrp Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58: Arg AlaTyr Arg Tyr Arg Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: Arg TrpArg Glu Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: Arg HisPro Trp Thr Glu Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: Cys AsnTrp Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: Arg AlaTyr Arg Tyr Arg Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: Glu ArgArg Val Pro 1 5 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64: Arg LeuLeu Leu Trp Gln Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: Gly ArgGly Ala Gly 1 5 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: Phe GlySer Phe Glu Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: Cys ArgTrp Thr Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: Arg ArgTrp Phe Asp Gly Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: Cys AsnTrp Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: Arg AlaTyr Arg Tyr Arg Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: Ala ValThr Val Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: Gly ArgGly Asp Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73: Gly GlnArg Thr Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: Gly GlnArg Thr Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77: Gly GlnArg Thr Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79: Leu ArgTyr Arg Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80: Gly TrpArg Trp Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81: Gly GlnArg Thr Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83: Gly GlnArg Thr Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 85: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85: Leu ArgTyr Arg Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: Gly TrpArg Trp Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87: Leu ArgTyr Arg Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88: Gly TrpArg Trp Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89: Gly GlnArg Thr Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91: Leu ArgTyr Arg Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92: Gly TrpArg Trp Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 93: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93: GCAGTTACCGTGCGT 15 (2) INFORMATION FOR SEQ ID NO: 94: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94: Ala ValTrp Val Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 95: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95: GGCCGTGGTGACAGCCCAGC GAGC 24 (2) INFORMATION FOR SEQ ID NO: 96: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96: Gly ArgGly Asp Ser Pro Ala Ser 1 5 (2) INFORMATION FOR SEQ ID NO: 97: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleicacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97:TCGAGGTTGC GGCGG 15 (2) INFORMATION FOR SEQ ID NO: 98: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98: Ser ArgLeu Arg Arg 1 5 (2) INFORMATION FOR SEQ ID NO: 99: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99: CCGCCGTGGAGGGTG 15 (2) INFORMATION FOR SEQ ID NO: 100: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100: Pro ProTrp Arg Val 1 5 (2) INFORMATION FOR SEQ ID NO: 101: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101: GGTCAGCGAACTTTT 15 (2) INFORMATION FOR SEQ ID NO: 102: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102: Gly GlnArg Trp Phe 1 5 (2) INFORMATION FOR SEQ ID NO: 103: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103: AGGCGGTGGTGGGCT 15 (2) INFORMATION FOR SEQ ID NO: 104: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104: Arg ArgTrp Trp Ala 1 5 (2) INFORMATION FOR SEQ ID NO: 105: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105: GCGAGGTGGACGCTT 15 (2) INFORMATION FOR SEQ ID NO: 106: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106: Ala ArgTrp Thr Leu 1 5 (2) INFORMATION FOR SEQ ID NO: 107: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii)HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi)ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107: AGGCGGTGGTGGTGG 15 (2) INFORMATION FOR SEQ ID NO: 108: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108: Arg ArgTrp Trp Trp 1 5 (2) INFORMATION FOR SEQ ID NO: 109: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 5 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109: Gly LysLys Gly Lys 1 5 (2) INFORMATION FOR SEQ ID NO: 110: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 94 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110: Val SerAsp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr Ser 1 5 10 15Leu Leu Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg Ile 2025 30 Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr ValPro 35 40 45 50 Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro GlyVal Asp Tyr 55 60 65 Thr Ile Thr Val Tyr Ala Val Thr Gly Arg Gly Asp SerPro Ala Ser Ser 70 75 80 85 Lys Pro Ile Ser Ile Asn Tyr Arg Thr 90 (2)INFORMATION FOR SEQ ID NO: 111: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 308 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single(D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO(iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE:(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111: CATATGCAGG TTTCTGATGTTCCGCGTGAC CTGGAAGTTG TTGCTGCGAC CCCGACTAGC 60 CTGCTGATCA GCTGGGATGCTCCTGCAGTT ACCGTGCGTT ATTACCGTAT CACGTACGGT 120 GAAACCGGTG GTAACTCCCCGGTTCAGGAA TTCACTGTAC CTGGTTCCAA GTCTACTGCT 180 ACCATCAGCG GCCTGAAACCGGGTGTCGAC TATACCATCA CTGTATACGC TGTTACTGGC 240 CGTGGTGACA GCCCAGCGAGCTCCAAGCCA ATCTCGATTA ACTACCGTAC CTAGTAACTC 300 GAGGATCC 308 (2)INFORMATION FOR SEQ ID NO: 112: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 96 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 112: Met Gln Val Ser Asp Val Pro ArgAsp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile SerTrp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr Arg Ile 20 25 30 35 Thr TyrGly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr Val Pro Gly 40 45 50Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr Ile55 60 65 70 Thr Val Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro Ala Ser SerLys Pro Ile 75 80 85 90 Ser Ile Asn Tyr Arg Thr 95 (2) INFORMATION FORSEQ ID NO: 113: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3 amino acids(B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 113: Arg Gly Asp 1 (2) INFORMATION FOR SEQ ID NO: 114: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 amino acids (B) TYPE: aminoacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:114: Met Gly Ser Ser His His His His His His Ser Ser Gly Leu Val Pro 1 510 15 Arg Gly Ser His 20 (2) INFORMATION FOR SEQ ID NO: 115: (i)SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: aminoacid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE:peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE:internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115: Gly Gln Arg Thr Phe Arg Arg Trp Trp Ala 1 5 10 (2) INFORMATION FORSEQ ID NO: 116: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids(B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii)MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v)FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION:SEQ ID NO: 116: Leu Arg Tyr Arg Ser Gly Trp Arg Trp Arg 1 5 10 (2)INFORMATION FOR SEQ ID NO: 117: (i) SEQUENCE CHARACTERISTICS: (A)LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D)TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv)ANTI-SENSE: NO (v) FRAGMENT TYPE: internal (vi) ORIGINAL SOURCE: (xi)SEQUENCE DESCRIPTION: SEQ ID NO: 117: Cys Asn Trp Arg Arg Arg Ala TyrArg Tyr Trp Arg 1 5 10 (2) INFORMATION FOR SEQ ID NO: 118: (i) SEQUENCECHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C)STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide(iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: internal(vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118: Ala ArgMet Arg Glu Arg Trp Leu Arg Gly Arg Tyr 1 5 10

What is claimed is:
 1. A fibronectin type III (Fn3) polypeptide monobodycomprising a plurality of Fn3 β-strand domain sequences that are linkedto a plurality of loop region sequences, wherein one or more of themonobody loop region sequences vary by deletion, insertion orreplacement of at least two amino acids from the corresponding loopregion sequences in wild-type Fn3, and wherein the β-strand domains ofthe monobody have at least a 50% total amino acid sequence homology tothe corresponding amino acid sequence of wild-type Fn3's β-strand domainsequences.
 2. The monobody of claim 1, wherein at least one loop regionis capable of binding to a specific binding partner (SBP) to form apolypeptide:SBP complex having a dissociation constant of less than 10⁻⁶moles/liter.
 3. The monobody of claim 1, wherein at least one loopregion is capable of catalyzing a chemical reaction with a catalyzedrate constant (k_(cat)) and an uncatalyzed rate constant (k_(uncat))such that the ratio of k_(cat)/k_(uncat), is greater than
 10. 4. Themonobody of claim 1, wherein one or more of the loop regions compriseamino acid residues: i) from 15 to 16 inclusive in an AB loop; ii) from22 to 30 inclusive in a BC loop; iii) from 39 to 45 inclusive in a CDloop; iv) from 51 to 55 inclusive in a DE loop; v) from 60 to 66inclusive in an EF loop; and vi) from 76 to 87 inclusive in an FG loop.5. The monobody of claim 1, wherein the monobody loop region sequencesvary from the wild-type Fn3 loop region sequences by the deletion orreplacement of at least 2 amino acids.
 6. The monobody of claim 1,wherein the monobody loop region sequences vary from the wild-type Fn3loop region sequences by the insertion of from 3 to 25 amino acids. 7.An isolated nucleic acid molecule encoding the polypeptide monobody ofclaim
 1. 8. An expression vector comprising an expression cassetteoperably linked to the nucleic acid molecule of claim
 7. 9. Theexpression vector of claim 8, wherein the expression vector is an M13phage-based plasmid.
 10. A host cell comprising the vector of claim 8.11. A method of preparing a fibronectin type III (Fn3) polypeptidemonobody comprising the steps of: a) providing a DNA sequence encoding aplurality of Fn3 β-strand domain sequences that are linked to aplurality of loop region sequences wherein at least one loop regioncontains a unique restriction enzyme site; b) cleaving the DNA sequenceat the unique restriction site; c) inserting into the restriction site aDNA segment known to encode a peptide capable of binding to a specificbinding partner (SBP) or a transition state analog compound (TSAC) so asto yield a DNA molecule comprising the insertion and the DNA sequence of(a); and d) expressing the DNA molecule so as to yield polypeptidemonobody.
 12. A method of preparing a fibronectin type III (Fn3)polypeptide monobody comprising the steps of: (a) providing areplicatable DNA sequence encoding a plurality of Fn3 β-strand domainsequences that are linked to a plurality of loop region sequences,wherein the nucleotide sequence of at least one loop region is known;(b) preparing polymerase chain reaction (PCR) primers sufficientlycomplementary to the known loop sequence so as to be hybridizable underPCR conditions, wherein at least one of the primers contains a modifiednucleic acid sequence to be inserted into the DNA; (c) performingpolymerase chain reaction using the DNA sequence of (a) and the primersof (b); (d) annealing and extending the reaction products of (c) so asto yield a DNA product; and (e) expressing the polypeptide monobodyencoded by the DNA product of (d).
 13. A method of preparing afibronectin type III (Fn3) polypeptide monobody comprising the steps of:a) providing a replicatable DNA sequence encoding a plurality of Fn3β-strand domain sequences that are linked to a plurality of loop regionsequences, wherein the nucleotide sequence of at least one loop regionis known; b) performing site-directed mutagenesis of at least one loopregion so as to create a DNA sequence comprising an insertion mutation;and c) expressing the polypeptide monobody encoded by the DNA sequencecomprising the insertion mutation.
 14. A kit for performing the methodof any one of claims 11-13, comprising a replicatable DNA encoding aplurality of Fn3 β-strand domain sequences that are linked to aplurality of loop region sequences.
 15. A variegated nucleic acidlibrary encoding Fn3 polypeptide monobodies comprising a plurality ofnucleic acid species each comprising a plurality of loop regions,wherein the species encode a plurality of Fn3 β-strand domain sequencesthat are linked to a plurality of loop region sequences, wherein one ormore of the loop region sequences vary by deletion, insertion orreplacement of at least two amino acids from corresponding loop regionsequences in wild-type Fn3, and wherein the β-strand domain sequences ofthe monobody have at least a 50% total amino acid sequence homology tothe corresponding amino acid sequences of β-strand domain sequences ofthe wild-type Fn3.
 16. The variegated nucleic acid library of claim 15,wherein one or more of the loop regions encodes: i) an AB amino acidloop from residue 15 to 16 inclusive; ii) a BC amino acid loop fromresidue 22 to 30 inclusive; iii) a CD amino acid loop from residue 39 to45 inclusive; iv) a DE amino acid loop from residue 51 to 55 inclusive;v) an EF amino acid loop from residue 60 to 66 inclusive; and vi) an FGamino acid loop from residue 76 to 87 inclusive.
 17. The variegatednucleic acid library of claim 15, wherein the loop region sequences varyfrom the wild-type Fn3 loop region sequences by the deletion orreplacement of at least 2 amino acids.
 18. The variegated nucleic acidlibrary of claim 15, wherein the monobody loop region sequences varyfrom the wild-type Fn3 loop region sequences by the insertion of from 3to 25 amino acids.
 19. The variegated nucleic acid library of claim 15,wherein a variegated nucleic acid sequence comprising from 6 to 75nucleic acid bases is inserted in any one of the loop regions of saidspecies.
 20. The variegated nucleic acid library of claim 15, whereinthe variegated sequence is constructed so as to avoid one or more codonsselected from the group consisting of those codons encoding cysteine orthe stop codon.
 21. The variegated nucleic acid library of claim 15,wherein the variegated nucleic acid sequence is located in the BC loop.22. The variegated nucleic acid library of claim 15, wherein thevariegated nucleic acid sequence is located in the DE loop.
 23. Thevariegated nucleic acid library of claim 15, wherein the variegatednucleic acid sequence is located in the FG loop.
 24. The variegatednucleic acid library of claim 15, wherein the variegated nucleic acidsequence is located in the AB loop.
 25. The variegated nucleic acidlibrary of claim 15, wherein the variegated nucleic acid sequence islocated in the CD loop.
 26. The variegated nucleic acid library of claim15, wherein the variegated nucleic acid sequence is located in the EFloop.
 27. A peptide display library derived from the variegated nucleicacid library of claim
 15. 28. A peptide display library of claim 27,wherein the peptide is displayed on the surface of a bacteriophage orvirus.
 29. A peptide display library of claim 28, wherein thebacteriophage is M13 or fd.
 30. A method of identifying the amino acidsequence of a polypeptide molecule capable of binding to a specificbinding partner (SBP) so as to form a polypeptide:SSP complex whereinthe dissociation constant of the said polypeptide:SBP complex is lessthan 10⁻⁶ moles/liter, comprising the steps of: a) providing a peptidedisplay library according to claim 28; b) contacting the peptide displaylibrary of (a) with an immobilized or separable SBP; c) separating thepeptide:SBP complexes from the free peptides, d) causing the replicationof the separated peptides of (c) so as to result in a new peptidedisplay library distinguished from that in (a) by having a lowereddiversity and by being enriched in displayed peptides capable of bindingthe SBP; e) optionally repeating steps (b), (c), and (d) with the newlibrary of (d); and f) determining the nucleic acid sequence of theregion encoding the displayed peptide of a species from (d) and deducingthe peptide sequence capable of binding to the SBP.
 31. A method ofpreparing a variegated nucleic acid library encoding Fn3 polypeptidemonobodies having a plurality of nucleic acid species each comprising aplurality of loop regions, wherein the species encode a plurality of Fn3β-strand domain sequences that are linked to a plurality of loop regionsequences, wherein one or more of the loop region sequences vary bydeletion, insertion or replacement of at least two amino acids fromcorresponding loop region sequences in wild-type Fn3, and wherein theβ-strand domain sequences of the monobody have at least a 50% totalamino acid sequence homology to the corresponding amino acid sequencesof β-strand domain sequences of the wild-type Fn3, comprising the stepsof a) preparing an Fn3 polypeptide monobody having a predeterminedsequence; b) contacting the polypeptide with a specific binding partner(SBP) so as to form a polypeptide:SSP complex wherein the dissociationconstant of the said polypeptide:SBP complex is less than 10⁻⁶moles/liter; c) determining the binding structure of the polypeptide:SBPcomplex by nuclear magnetic resonance spectroscopy or X-raycrystallography; and d) preparing the variegated nucleic acid library,wherein the variegation is performed at positions in the nucleic acidsequence which, from the information provided in (c), result in one ormore polypeptides with improved binding to the SBP.
 32. A method ofidentifying the amino acid sequence of a polypeptide molecule capable ofcatalyzing a chemical reaction with a catalyzed rate constant, k_(cat),and an uncatalyzed rate constant, k_(uncat), such that the ratio ofk_(cat)/k_(uncat) is greater than 10, comprising the steps of: a)providing a peptide display library according to claim 28; b) contactingthe peptide display library of (a) with an immobilized or separabletransition state analog compound (TSAC) representing the approximatemolecular transition state of the chemical reaction; c) separating thepeptide:TSAC complexes from the free peptides; d) causing thereplication of the separated peptides of (c) so as to result in a newpeptide display library distinguished from that in (a) by having alowered diversity and by being enriched in displayed peptides capable ofbinding the TSAC; e) optionally repeating steps (b), (c), and (d) withthe new library of (d); and f) determining the nucleic acid sequence ofthe region encoding the displayed peptide of a species from (d) andhence deducing the peptide sequence.
 33. A method of preparing avariegated nucleic acid library encoding Fn3 polypeptide monobodieshaving a plurality of nucleic acid species each comprising a pluralityof loop regions, wherein the species encode a plurality of Fn3 β-stranddomain sequences that are linked to a plurality of loop regionsequences, wherein one or more of the loop region sequences vary bydeletion, insertion or replacement of at least two amino acids fromcorresponding loop region sequences in wild-type Fn3, and wherein theβ-strand domain sequences of the monobody have at least a 50% totalamino acid sequence homology to the corresponding amino acid sequencesof β-strand domain sequences of the wild-type Fn3, comprising the stepsof a) preparing an Fn3 polypeptide monobody having a predeterminedsequence, wherein the polypeptide is capable of catalyzing a chemicalreaction with a catalyzed rate constant, k_(cat), and an uncatalyzedrate constant, k_(uncat), such that the ratio of k_(cat)/k_(uncat) isgreater than 10; b) contacting the polypeptide with an immobilized orseparable transition state analog compound (TSAC) representing theapproximate molecular transition state of the chemical reaction; c)determining the binding structure of the polypeptide:TSAC complex bynuclear magnetic resonance spectroscopy or X-ray crystallography; and d)preparing the variegated nucleic acid library, wherein the variegationis performed at positions in the nucleic acid sequence which, from theinformation provided in (c), result in one or more polypeptides withimproved binding to or stabilization of the TSAC.
 34. An isolatedpolypeptide identified by the method of claim 30
 35. An isolatedpolypeptide identified by the method of claim
 32. 36. A kit foridentifying the amino acid sequence of a polypeptide molecule capable ofbinding to a specific binding partner (SBP) so as to form apolypeptide:SSP complex wherein the dissociation constant of the saidpolypeptide:SBP complex is less than 10⁻⁶ moles/liter, comprising thepeptide display library of claim
 28. 37. A kit for identifying the aminoacid sequence of a polypeptide molecule capable of catalyzing a chemicalreaction with a catalyzed rate constant, k_(cat), and an uncatalyzedrate constant, k_(uncat), such that the ratio of k_(cat)/k_(uncat) isgreater than 10, comprising the peptide display library of claim
 28. 38.A polypeptide derived by using the kit of claim
 36. 39. A polypeptidederived by using the kit of claim
 37. 40. A fibronectin type III tenthfibronectin unit (Fn3fn10) polypeptide monobody comprising at least twoFn3fn10 β-strand domain sequences with a loop region sequence linkedbetween each Fn3fn10 β-strand domain sequence, wherein at least onemonobody loop region sequence varies as compared to the wild-type loopregion sequence by deletion of at least two amino acids in the loopregion sequence, insertion of one to 25 amino acids, or replacement ofat least two amino acids in the loop region sequence to form a variedloop region, and wherein at least one of the varied loop regions bindsto a specific binding partner (SBP) to form a polypeptide:SBP complex.41. The monobody of claim 40, wherein at least one loop region binds toa specific binding partner (SBP) to form a polypeptide:SBP complexhaving a dissociation constant of less than 10⁻⁶ moles/liter.
 42. Themonobody of claim 40, wherein a loop region comprises amino acidresidues: i) from 15 to 16 inclusive in an AB loop; ii) from 22 to 30inclusive in a BC loop; iii) from 39 to 45 inclusive in a CD loop; iv)from 51 to 55 inclusive in a DE loop; v) from 60 to 66 inclusive in anEF loop; or vi) from 76 to 87 inclusive in an FG loop.
 43. The monobodyof claim 40, wherein the monobody loop region sequence varies from thewild-type Fn3 loop region sequence by the deletion or replacement of atleast two amino acids in the loop region.
 44. The monobody of claim 40,wherein the monobody loop region sequence varies from the wild-typeFn3fn10 loop region sequence by the insertion of from 3 to 25 aminoacids.